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TEMPORAL TRENDS IN PERCUTANEOUS CORONARY INTERVENTION AND 
ASSOCIATED IMPACT ON CLINICAL AND PATIENT-REPORTED OUTCOMES 
 Lakshmi Venkitachalam, PhD 
University of Pittsburgh, 2007
Cardiovascular disease remains the leading cause of mortality and morbidity in the 21st century 
accounting for about one-fifth of deaths overall each year in the United States. Percutaneous 
coronary intervention (PCI), used initially in the 1970s, is now the most commonly performed 
non-surgical procedure for atherosclerotic coronary disease. PCI, in the last three decades, 
witnessed rapid advancements, both technologically (from balloons to stents and atherectomy 
devices) as well as in adjunct therapy (antithrombotics, fibrinolytics and antiplatelet agents). The 
purpose of this dissertation, designed as three research papers, was to capture this evolution and 
the associated impact on clinical and patient-reported outcomes, in the prospective, multicenter 
NHLBI-sponsored 1985-86 PTCA (era of balloon angioplasty) and 1997-2004 Dynamic (era of 
stents, brachytherapy and drug-eluting stents) registries.  
Temporal trends in clinical practice revealed the heterogeneity in patients (and lesions) 
undergoing PCI and yet, consistent dramatic improvements were seen in procedural success with 
reduced need for repeat procedures; little impact was observed in one-year mortality rates. In the 
Dynamic Registry, significant reductions in one year prevalence and risk of patient-reported 
angina were observed concurrent to use of new evidence-based secondary pharmacological 
therapy. In contemporary practice, women and patients with prior/repeat PCI continued to be at 
high-risk for post-procedural symptoms. Supplemental therapy, following initial PCI, was more 
often pharmacological with concomitant reduction in bypass surgery and repeat PCI. On average, 
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patient-reported quality of life improved over time and was influenced by both symptom status 
and the need and type of supplemental therapy.  
Indeed, these findings reflect the dynamic nature of PCI with an increasingly 
heterogeneous treatment population and yet favorable procedural outcomes (procedural success, 
reduced repeat procedures, greater relief of symptoms). More importantly, they highlight the 
continued lack of impact on mortality and identify symptom-prone subsets in contemporary 
practice. This time-sensitive documentation is especially fitting given the 300% increase in the 
number of PCIs since its initial use. From a public health point of view, any treatment modality 
applied in this magnitude warrants constant surveillance, more so with the emerging safety 
concerns, and this underscores the importance of well-designed registries.
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 OVERVIEW AND OBJECTIVE 
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity, worldwide, and 
coronary artery disease (CAD) is the most common cause of CVD-related deaths. The advent of 
percutaneous coronary intervention (PCI) revolutionized treatment of CAD and is currently one 
of the most commonly performed non-surgical procedures, both in the U.S. and abroad. The field 
of PCI, per se, has seen rapid technological developments since its initial use in 1977 and this in 
turn, has widened the profile of patients and lesions undergoing the procedure.  
 The purpose of this dissertation, therefore, is to document evolution of PCI in over two 
decades of clinical practice and its associated impact on outcomes from perspective of both the 
provider (cardiologist) and the receiver (the patient). Specifically, the objectives of the three 
research papers are: 
1. To document trends in patient, lesion,  and procedural characteristics, and compare in-hospital 
and one year outcomes - from the era of balloon angioplasty (1985-86 PTCA registry) to that of 
stents (1997-2004 Dynamic registry). 
2. To document trends in post-procedural angina, at one year of follow-up, across the four 
recruitment waves of the Dynamic registry, representing the advent (wave 1) and uniform use 
(wave 2) of bare metal stents, intra-coronary radiation (wave 3) and advent of drug-eluting stents 
(wave 4) and identify predictors of symptoms in contemporary practice.  
3. To evaluate whether improvements in PCI has influenced the ‘price’ for achieving symptom-
free status and the associated impact on patient-reported quality of life indicators. 
 
 1 
 BACKGROUND 
CORONARY ARTERY DISEASE 
CAD, the most common form of cardiovascular disease in adulthood, is a pathological condition 
in which there is obstruction to the blood flow in the coronary arteries that supply the heart. 
Deposition of atheromatous plaques in the coronaries results in narrowing of the vessel lumen 
reducing blood supply to the myocardium. The spectrum of clinical severity ranges from 
asymptomatic status to symptoms that include chest pain (angina), breathlessness (dyspnoea), 
fatigue, palpitations, and acute events including myocardial infarction (MI), congestive heart 
failure  (CHF) and even death. The risk factors for CAD can be classified as modifiable and non-
modifiable. Family history and sex belong to the non-modifiable category while lifestyle 
behaviors such as lack of physical activity, poor dietary habits and smoking are some of the 
modifiable ones. Co-morbid conditions such as obesity, hypertension, hyperlipidemia and 
diabetes are also known to increase the risk of CAD. 
PUBLIC HEALTH BURDEN 
CVD remains the leading cause of mortality and morbidity in the 21st century. In the United 
States, CVD is the leading cause of death for both men and women and across all races, 
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 accounting for about one-fifth of deaths overall each year 1. As of 2003, CVD was prevalent in 
71,300,000 Americans, of whom 13,200,000 were reported to have CAD. Approximately 53% of 
CVD mortality was attributed to CAD followed by 18% for stroke. Although death rates from 
CAD declined 26.5% from 1992 to 2002, the actual number of deaths declined by only 9.9%; 
83% of those who died from CAD were over 65 years of age.  
Apart from the huge clinical impact, the financial burden associated with CVD is high 
with cost of CVD in 2005 estimated at $393.5 billion; the amount for CAD alone was $142.1 
billion dollars 1. Surveys conducted during 1987-2000, showed that among the top 15 most 
costly medical conditions, heart disease occupies first place with an 8.1% increase in total 
healthcare spending. These statistics provide compelling evidence of the impact of CAD on the 
society and the need to identify and assess effective preventive and treatment strategies. 
Although primary prevention is ideal, the pressure to treat the already prevalent disease burden is 
immense. 
TREATMENT OF CORONARY ARTERY DISEASE 
In addition to behavioral and risk factor management, the treatment options for CAD ranges 
from non-invasive pharmacological therapy to invasive revascularization procedures (coronary 
artery bypass grafting (CABG) and percutaneous interventions) 2. 
 Pharmacological therapy is often the first line of treatment and includes anti-anginal 
medications such as nitrates, beta-blockers and calcium channel blockers. In addition to these 
drugs, aspirin, an antiplatelet agent, has shown to be especially effective in early stages of MI 
and reduction of cardiovascular mortality 3. Prior to the advent of percutaneous coronary 
 3 
 intervention (PCI), CABG was the only other alternative mode of CAD therapy. Saphenous vein 
grafts, harvested from the patient’s legs and fashioned as conduits, were used to bypass coronary 
lesions to supply blood to distal portions. Randomized trials like the Veterans Administration 
(VA) study 4, Coronary Artery Surgery Study (CASS) 5 and European Coronary Surgery Study 6, 
compared medical therapy to surgical treatment and found that both options had similar survival 
benefits except in multivessel disease or poor ventricular function, wherein surgery was better. 
However, this benefit seen with CABG lasted for only 5-7 years after which symptoms returned 
with increasing risk of mortality 7. This was attributed to degeneration of the vein grafts and 
prompted use of arterial conduits like the internal mammary artery, which is currently the 
conduit of choice. 
Percutaneous Coronary Intervention 
The concept of PCI was introduced in 1964 and balloon angioplasty was first performed to dilate 
a single lesion in a 38-yr old man in Switzerland in 1977 8. Ever since then and up to the 
approval of the first drug-eluting stents, this field has undergone rapid developments. In the year 
2003, approximately 664,000 procedures were performed on 652,000 patients in the U.S., an 
estimated increase of more than 300% since 1987 (Appendix A) 1. 
 The beneficial effect of balloon angioplasty was attributed to stretching and tearing of the 
plaque, accompanied by its redistribution 9. Although this resulted in initial success rates of 86-
88%, complications such as abrupt vessel closure, due to dissection and / or thrombus 10, 
necessitated emergency surgery as a bail-out option. This prompted development of devices that 
could incise and/or remove plaques (cutting balloons, atherectomy devices), ablate lesions 
(Excimer angioplasty, brachytherapy) or serve as scaffolds (metallic stents) that prevent vessel 
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 recoil. Of these, use of bare-metal stents (BMS) resulted in drastic reduction in acute 
complications, simultaneously increasing the success rates. However, they triggered thrombus 
formation and inflammatory responses resulting in restenosis that necessitated re-intervention. 
The latest in the armamentarium are drug-eluting stents (DES) – polymer-based stents with drug 
coating with immunosuppressant and antithrombotic properties. Numerous trials, conducted 
within a short time frame, showed dramatic improvements with restenosis rates as low as 0% 11 , 
12 , 13. Paralleling these technological developments, are improvements in adjunct therapy which 
include antiplatelets (aspirin, ticlopidine, clopidogrel) and anticoagulants (hirudin, bivalirudin 
and low-molecular weight heparin, glycoprotein IIb/IIIa platelet receptor inhibitors).  
 However, in spite of this progress, the field of PCI now appears to be at crossroads. Long 
term follow-up of the DES has unearthed concerns – increased risk of mortality and late stent 
thrombosis 14, 15 - that, if validated, could amount to a major public health burden. It has also 
brought to light, concerns of dual antiplatelet therapy use – their appropriate duration that 
depends on the stent type as well as patients’ responsiveness and compliance to these 
medications. Overall, since initial use of the procedure, it appears that the profile of patients (and 
lesions) undergoing PCI has become quite heterogeneous, to the extent that almost half of the 
procedures today are performed under ‘off-label’ or ‘untested’ circumstances 16. This, therefore, 
makes it vital to have a time-sensitive documentation of the evolving real world clinical practice 
and its associated impact, so as to provide the much-needed ‘big picture’, in the context of which 
future developments and concerns can be assessed.  
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 NATIONAL HEART, LUNG AND BLOOD INSTITUTE (NHLBI)-SPONSORED 1985-86 
PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA) AND 
1997-2004 DYNAMIC REGISTRIES 
Randomized clinical trials (RCT) are considered the gold standard in evidence-based medicine. 
However, in a field such as PCI with rapid technological progress, new devices are often 
introduced after initiation of a RCT and are in widespread use by the time the findings are 
available. Therefore, when angioplasty became available for clinical use, the NHLBI set up the 
1977-1981 PTCA registry to track use and performance of the procedure in the real world. 
Following the rapid uptake of the procedure by the medical community, this registry was 
reopened in 1985 17, 18 to verify and quantify the progress in the field. This registry recruited and 
followed 2431 consecutive patients, with no prior revascularization, undergoing angioplasty PCI 
from 16 centers in North America and Canada (Appendix II – to be included). The findings from 
this 1985-86 PTCA registry demonstrated that procedural success of angioplasty had improved 
and the need for CABG had decreased, and called for a randomized trial to compare this 
procedure to CABG. This registry was also showed racial difference in cardiovascular risk 
profile of patients undergoing PTCA 19 and that women had significantly increased in-hospital 
mortality rates and angina at follow-up 20, 21.  
 Although during the PTCA registries, balloons were the only device available for use, the 
field witnessed extensive and rapid technological developments with the introduction of 
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 atherectomy devices and bare metal stents. Given the pressing need to characterize contemporary 
practice, the Dynamic registry (DR) was developed in 1997 to recruit consecutive patients 
undergoing PCI in waves - 1: 1997-98, 2: 1999, 3: 2001-02, 4: 2004. This innovative design 
allowed for assessing safety and effectiveness in this rapidly changing field and included all 
catheter-based cases, regardless of whether it was first or repeat procedure. The registry recruited 
from 15-20 centers, of which 10 were from the 1985-86 PTCA registry (Appendix B). To allow 
sufficient representation of all the sites, enrollment of white males were discontinued when 120 
white males were enrolled at a site or when 1,600 white patients were enrolled in the study as a 
whole. All consecutive minority and women patients were then recruited until 2,000 patients 
were enrolled across all sites. Recruitment was monitored by the Coordinating center, using 
screening logs, faxed to the center on a weekly basis. All research coordinators were trained in 
data collection procedures prior to patient enrollment. Written informed consent was obtained 
from participants to be contacted after discharge, and then annually, for health status 
information. Demographic information, medical history, angiographic and procedural details, 
and follow-up, information including repeat revascularization, were ascertained. The study 
protocol was approved by the Institutional Review Board of the University of Pittsburgh, the 
coordinating center, and all the sites involved.  
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 1.1 ABSTRACT 
Since its initial use, percutaneous coronary intervention (PCI) has witnessed rapid advancements 
in technology and adjunct therapy. The purpose of this analysis was to document this evolution 
and the associated impact on one year clinical outcomes. Temporal trend in de novo PCI was 
analyzed using consecutive cases in the NHLBI-sponsored 1985-86 PTCA registry and  
Dynamic registry (DR) waves: 1997-98 (bare metal stents), 1999 (uniform use of stents), 2001-
02 (brachytherapy) and 2004 (drug-eluting stents). Patient and procedural profiles have expanded 
to include more elderly patients, those with concomitant comorbidities and rise in urgent 
procedures. Use of stents have increased over time from 70% in wave 1 (only bare metal) to 95% 
(72% drug-eluting) in wave 4; adjunct therapy including IIb/IIIa inhibitors (25% in wave 1 to 
37% in wave 4) and antiplatelet agents (52% in wave 1 to 85% in wave 4) have been utilized 
more frequently. Despite the higher clinical severity in the stent era, procedural success and 
reduction in abrupt closures were achieved more often. Although little impact was observed on 
mortality rates, significant reduction was seen in 1-year adjusted risk estimates of late repeat PCI 
(hazard ratio: 0.7, 0.5, 0.5 and 0.3 for DR waves 1,2,3,4 compared to the PTCA registry) and 
death/myocardial infarction (hazard ratio: 0.7, 0.7, 0.6 and 0.7 for DR waves 1,2,3,4 compared to 
the PTCA registry). In the past two decades, PCI has evolved considerably to include more 
urgent, comorbid cases, yet achieving appreciable success rates with reduced need for repeat 
revascularization.   
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 1.2 BACKGROUND 
Percutaneous coronary intervention (PCI) is one of the most commonly performed non-surgical 
procedures, both in the U.S. 1 and worldwide 22, 23. Ever since its initial use in the treatment of 
atherosclerosis 8, the field has witnessed rapid advancements, both technologically (from 
balloons to stents and atherectomy devices) as well as in adjunct therapy (antithrombotics, 
fibrinolytics and antiplatelet agents). Concomitantly, the profile of patients (and lesions) 
undergoing PCI in the last two decades, has become heterogeneous 24, 25. The multicenter 
NHLBI-sponsored 1985-86 PTCA 26 and 1997-2004 Dynamic registries (DR) 24, 27 were 
specifically initiated to document this evolution and taken together, form a systematic and 
comprehensive source of prospective data, spanning two decades of real world practice.  The 
purpose of our analysis, therefore, is two-fold – 1) to document trends in patient, lesion,  and 
procedural characteristics, and 2) to compare in-hospital and one year outcomes - from the era of 
balloon angioplasty (1985-86 PTCA registry) to that of the stents (Dynamic registry). This time-
sensitive appraisal is especially fitting at this juncture wherein the field is at the crossroads - 
restenosis, the long-time Achilles heel, may have been overcome 12, 13 , but there are emerging 
concerns of late stent thrombosis 14 and long-term safety 15. 
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 1.3 METHODS 
1.3.1 NHLBI-sponsored 1985-86 PTCA and 1997-2004 Dynamic Registries – design and 
data collection 
The design and study population of the registries have been described in earlier reports 24,26,17,18. 
Briefly, consecutive patients undergoing angioplasty for the first time were enrolled from 16 
centers in the PTCA registry. The DR, developed in 1997, enrolled consecutive patients 
undergoing PCI, from 15-20 centers, in the following waves – 1: 1997-1998, 2: 1999, 3: 2001-
02, 4: 2004; the cohort was enriched with oversampling of women and minorities. All research 
coordinators were trained in data collection procedures prior to patient enrollment and 
information on patient demographics, medical history, angiographic and procedural details, was 
ascertained. Standard definitions, as used in previous reports 18, 5, were applied and included the 
following: lesions were considered successfully treated when an absolute reduction of 20% in 
lesion severity and final diameter stenosis <50% was achieved; angiographic success was 
classified as either partial (some but not all attempted lesions successfully treated) or total (all 
attempted lesions successfully treated); procedural success was defined as achievement of either 
partial or total angiographic success without death, Q-wave myocardial infarction (MI), or 
emergency bypass surgery. For each cohort, the definition of MI was revised to match prevailing 
expert consensus - in the PTCA registry, it was defined as evidence of ≥ 2 of the following: (1) 
typical chest pain >20 minutes not relieved by nitroglycerin, (2) serial ECG recordings showing 
changes from baseline or serially in ST-T and/or Q-waves in ≥ 2 contiguous leads, or (3) serum 
enzyme elevation of CK-MB>5% of total CK (total CK>2x normal; LDH subtype 1>LDH 
subtype 2); in the DR, cardiac troponin levels was incorporated as a major criteria. Information 
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 on major outcomes, over one year of follow-up, including death from any cause, MI, CABG, and 
repeat PCI (only non-staged procedures performed during a subsequent hospitalization) were 
available. In each cohort, hospital records were examined to ensure consistency with respective 
protocol definitions. Written informed consent was obtained from participants to be contacted 
after discharge, and then annually, for health status information. The study protocol was 
approved by the Institutional Review Boards of the coordinating center (University of 
Pittsburgh) and all the clinical sites involved. 
1.3.2 Statistical Methods 
For sake of comparability with the PTCA registry, the enriched subset (women and minorities) 
and patients with prior PCI in DR were not included in this analysis. Trends in baseline 
characteristics - patient, procedural, lesion-specific and in-hospital outcomes – were assessed 
across the cohorts using the Cochran-Armitage test for dichotomous variables 28 and the 
Jonckeheere-Terpsta test for continuous and nominal/ordinal variables 29; continuous data were 
summarized as means and categorical variables as percentages.  
One-year Kaplan-Meier (KM) estimates of event rates for death, combined death/MI, 
repeat PCI, CABG, and repeat revascularizations (repeat PCI+CABG), were compared using log 
rank statistics. Hazard ratios for the DR waves were assessed using Cox regression models with 
the 1985-86 PTCA registry as reference. Proportionality assumptions were assessed and found to 
be satisfied for death and death/MI, but not for repeat procedures.  Therefore, repeat PCI, CABG 
and repeat revascularization were assessed at two time points – early (≤ 30 days) and late (31-
365 days) - from index procedure. Patients, whose first repeat PCI or CABG occurred within 30 
days from initial PCI, were censored for early events; analysis of late events included only those 
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 who did not undergo any repeat procedure within the first 30 days. Baseline characteristics 
(available in all 5 cohorts), with significant trend across the waves, were evaluated for univariate 
associations with the events and those significant at the 0.05 level were included in multivariable 
models); baseline ejection fraction was not considered due to substantial missing data (35%). For 
the final model, for each event, the ‘wave’ variable, representing the cohorts, was forced to stay 
in the model and remaining covariates selected using standard stepwise procedure (Pentry ≤ 
0.15, Pstay ≤ 0.10). All analyses were performed with SAS version 9.1 (SAS Institute Inc, NC). 
1.4 RESULTS  
1.4.1 Patient, lesion and procedural characteristics 
Compared to the PTCA registry, higher percentages of women, older patients, those with 
concomitant comorbidities (hypertension, diabetes and severe non-cardiac conditions including 
peripheral vascular disease) and prior bypass surgery were observed in the stent era (Table 1.1). 
Acute coronary syndrome (unstable angina/acute MI) remained the most common reason 
for revascularization over time, with a concomitant rise in non-elective procedures. The small yet 
increasing percentage of asymptomatic patients with evidence of CAD, undergoing PCI, is of 
note.  
Baseline disease burden, as reflected by number of lesions and vessels diseased, was 
higher in DR waves, however, procedural attempts more often involved single lesions and native 
vessels (Table 1.1). The proportion of graft body interventions was also generally higher in the 
stent era (4-5% vs 3%, Ptrend <0.01). Use of stents - either alone or in conjunction with balloons - 
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 increased from 70% in wave 1 (only bare metal) to 95% in wave 4 (72% drug-eluting); rotational 
or directional atherectomy and brachytherapy were used in fewer than 2% of patients. 
Glycoprotein IIb/IIIa inhibitors, not available in the PTCA registry, were used more frequently in 
the early waves; the drop in use seen in Wave 4 coincided with the introduction of bivalirudin 
(wave 4: 28%). Procedural use of ticlopidine and /or clopidogrel increased to 85% in the latest 
wave (Ptrend <0.001).  
The profile of attempted lesions was more severe in the DR – treated lesions were more 
often located in a graft or were calcified or thrombotic (Table 1.2). Although the attempted 
lesions were more often located in the left anterior descending artery, a small but significantly 
higher proportion of left main lesions were observed in recent waves. 
1.4.2 In-hospital outcomes and discharge medications 
With the introduction of stents, procedural success was achieved and maintained more often 
(PTCA registry: 82%, wave 1: 94%, wave 2: 95%, wave 3: 96%, wave 4: 96%; Ptrend: ≤0.001), 
despite treatment of more severe lesions. In contemporary practice, although complications such 
as local dissection and side branch occlusions were seen more often, significant reduction was 
observed in the rates of abrupt closures (Table 1.2). Trends in in-hospital events were also 
encouraging with a reduction in the rates of MI and CABG in the stent era; mortality rates were 
marginally, but not significantly higher in more recent cohorts (Figure 1.1).  
Mean length of hospital stay was reduced from 4.1 days in 1985-86 to an average of 2.5 days in 
the DR (Ptrend <0.001). Discharge rates of medications, including aspirin, beta-blockers and 
statins, recommended for secondary prevention of CAD, increased over time (Table 1.3).  
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 1.4.3 One year events 
 While the advent of stents coincided with an increase in crude one-year mortality rates, 
cumulative rates of death/MI did not vary significantly between the five cohorts (Figure 1.2). 
Similar pattern was observed in unadjusted risk estimates at one year – mortality risk was 
significantly higher and risk of death/MI was non-significantly lower for the DR waves, when 
compared to the PTCA registry (Table 1.4). However, adjustment for baseline cohort differences 
resulted in a significant reduction in combined mortality / MI risk in contemporary practice. 
Secondary univariate analysis of mortality was performed in selected subgroups. Crude 1-yr 
mortality rates, among ‘urgent cases, decreased over time (PTCA registry: 7%, wave1: 5%, wave 
2: 4%, wave 3: 5%, wave 4: 3%; Plogrank: 0.08), and among those with AMI, mortality risk at one 
year was non-significantly lower for the more recent waves (hazard ratios: 1.1, 1.0, 0.6, 0.9 for 
waves 1,2,3,4 compared to the PTCA registry). In the DR, use of stents was associated with 
lower mortality rates at one year (5% vs 7%, Plogrank: 0.02).  
Although the overall 1-yr rates of repeat revascularization (repeat PCI or CABG) were 
reduced from 29% in the PTCA registry to 11% in Wave 4, analyses by post-discharge interval 
revealed an interesting pattern. While the reduction in early CABG rates was initially steep, and 
plateauing thereafter, need for late CABG successively reduced over time (Figure 1.3). Risk of 
CABG for the DR waves, compared to the PTCA registry, was significantly lower within and 
after 30 days from initial PCI (Table 1.5). On the other hand, while cumulative rates of early 
repeat PCI significantly increased over time, need for late repeat PCI was significantly reduced 
across the cohorts (Figure 1.3). Risk of repeat PCI for DR waves, compared to the PTCA 
registry, followed similar pattern, both before and after adjustment for baseline differences 
(Table 1.5). Secondary analysis was performed in only those patients in whom both total 
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 angiographic and procedural success was achieved. The pattern of risk for repeat PCI remained 
similar to that seen in the overall cohort, i.e., need for early repeat PCI was higher and that for 
late repeat PCI was lower for patients in the Dynamic registry, when compared to those in the 
PTCA registry. 
1.5 DISCUSSION  
Our report gives a time-sensitive appraisal of PCI and associated outcomes spanning two 
decades of clinical practice in real-world consecutive patients. In contemporary practice, the high 
procedural success with improved effectiveness (reduced need for repeat PCI) at one year are 
especially noteworthy, given the widening patient and procedural profile. Although little impact 
was observed on mortality alone, the risk of death or MI was significantly lower and indicative 
of improved safety over time.  
1.5.1 The patient, lesion and procedure 
Technological improvements in the field of PCI were expected to widen the scope and feasibility 
of the procedure, and our report confirms this in a twenty-year snapshot of clinical practice. In 
contrast to the early days when PCI was primarily applied to discrete de novo lesions, the field 
has progressed to more challenging grounds, including older patients, with concomitant 
comorbidities, for acute MI, vein graft and calcified lesions. Angioplasties, these days, are also 
being performed under more emergent / urgent circumstances, when compared to the pre-stent 
era. As demonstrated in previous reports 24, 27, revascularization, at both the vessel and lesion 
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 level, was mostly selective, despite the greater disease burden seen at entry. The concept of 
complete anatomic revascularization stemmed from early CABG studies, which was then 
extended to the field of PCI. However, with more percutaneous procedures being performed for 
acute conditions, functional revascularization may be of greater immediate priority. It is also 
possible that, given the increasing proportion of older patients, baseline angiographic disease 
may be predominantly diffuse, permitting only partial rather than complete revascularization. 
1.5.2 In-hospital outcomes 
The heterogeneity of patients and lesions being treated over time is expected to impact 
procedural outcomes. When stents were initially introduced, indications widened to include 
complex lesions and were likely to be associated with high rates of distal embolization, 
dissections, and side branch occlusions 27, 30; subsequent reduction in these rates was attributed to 
improved operator technique and patient selection, facilitated by use of adjunct antithrombotic or 
fibrinolytic agents. Our report reconfirms this, wherein, angiographic / procedural success were 
achieved and maintained more often in the stent era, in addition to the overall low risk of 
immediate complications and reduced need for emergency CABG.  
1.5.3 Post-procedural mortality or MI 
Previous studies in PCI have demonstrated lack of impact on long-term all-cause mortality 24, 
31,32 and this has remained a matter of scientific inquiry. Other reports have shown a favorable 
impact on mortality and MI in high-risk settings such as acute MI 33, 34, 35 and cardiogenic shock 36,37,38. 
In our analysis, cumulative mortality rates increased with the advent of stents and plateaued 
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 thereafter, with higher unadjusted risk estimates for the more recent waves. However, given the 
severity of patients and lesions treated in the latter waves, it is encouraging that there was no 
significant impact on mortality. Additionally, as seen in our univariate analyses, mortality tended 
to be lower among urgent cases and those treated for AMI. Detailed risk-adjusted analysis is 
warranted in these subsets to delineate extent of improvement over time. The importance of 
monitoring cause-specific mortality has also been highlighted in recent report of long-term safety 
concerns with DES use 15. It would therefore, be interesting to assess impact on cardiac/non-
cardiac mortality ratio over time. 
In contrast to the trend in mortality alone, the impact on the combined endpoint of death 
or MI has been favorable and probably driven by MI. In the early days, PCI-related infarction 
was mostly attributed to abrupt closures and acute stent thrombosis. Stents were primarily 
designed to counteract vessel recoil and circumvent acute closure, and our data supports this. 
Additionally, the availability /use of improved adjunct drug regimen, including aspirin and 
clopidogrel, may have conferred added advantage. 
1.5.4 Repeat revascularization 
Improvements in PCI have been primarily aimed at reducing the need for repeat 
revascularization and as seen in our report, this depends on the post-discharge interval. Need for 
repeat PCI, within 30 days of index procedure, was higher in the stent era, albeit low absolute 
rates. In addition to reduced hospital stay, this could also represent a shift in favor of PCI, seen 
from the balloon era, where the only alternative to a failed initial PCI was CABG. On the other 
hand, a previous analysis of combined endpoint of 30-day events (including repeat target vessel 
PCI), showed very little improvement in the rates across the first three DR waves; factors that 
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 were associated with higher risk included multivessel disease, acuity, ostial lesions and 
pulmonary disease 39. 
The sustained reduction in the need for late repeat revascularization – repeat PCI or 
CABG – is what truly underscores the progress made in the field. The cohorts in this report are 
representative of advancements in PCI at the respective time periods – new devices, adjunct 
therapy, and improved antiplatelet regimen. The reduction in need for late PCI, observed when 
the analysis was restricted to patients with initial success– angiographic and procedural, is 
further proof for the favorable impact of the evolution in PCI. 
In addition to improvements in PCI, the role of concomitant pharmacological therapy 
cannot be overlooked. In the last two decades, a rise in the use of aspirin, beta blockers, plaque-
stabilizing/ regressing agents like statins and clopidogrel have been observed at discharge. There 
is greater need for their extended use and compliance, given the emerging concerns of disease 
progression 40 and stent thrombosis 41.  
1.5.5 Limitations 
Data for the analyses is obtained from a registry database - a design considered less rigorous than 
randomized trials (RCT). However, strict inclusion criteria in trials often lead to exclusion of 
patients with high-risk characteristics known to impact procedural outcome. The trial protocols 
often do not allow for premature antiplatelet/medication discontinuation, circumstances 
commonly encountered in the real world.  Thus, prospective enrollment of consecutive cases, as 
in our registries, permits better representation of contemporary practice with immediate 
applicability of results. RCTs are also designed for proving efficacy of treatments while 
registries help with the evaluation of safety and effectiveness, an example of which is the issue 
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 of DES-related thrombosis 42 that was identified using registry data, with no prior evidence in 
early trials 12,13. Model-building included only data available in all five cohorts, and information 
on bifurcations, ostial lesions and other lesion morphology were not used. Data on lifestyle 
modifications, bleeding complications, and medication dose were also not routinely collected. 
1.6 CONCLUSION 
In the past two decades, initial PCI has evolved considerably to include more urgent cases and 
higher percentage of patients with concomitant comorbidities, and yet achieved and maintained 
high success rates, with improved effectiveness (reduced need for repeat procedures) at one year. 
Extended follow-up is necessary to evaluate the duration of these benefits especially in clinically 
challenging subsets that include chronic total occlusions, bifurcation lesions, and patients with 
diabetes. Further research is also warranted to assess whether the observed trend in clinical 
success has been translated to improved symptom relief and quality of life of the patients. 
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 Table 1.1: Trends in patient demographics and procedural characteristics in the NHLBI-
sponsored PTCA (1985-86) and Dynamic (1997-2004) registries 
 
PTCA Dynamic Registry 
Registry 
 
Wave 1 Wave 2 Wave 3 Wave 4 
 
(N=2431) (N=1557) (N=1250) (N=1212) (N=1283) 
Patient demographics      
Age > 65 years, % ‡  28 42 45 48 47 
Women, % ‡ 26 32 32 35 31 
Race, %  ‡       
   White                92 86 87 88 84 
   Black         4 5 8 7 12 
   Asian  1 3 3 3 3 
   Hispanic       1 7 6 4 6 
Mean BMI, kg/m2  ‡ 27.0 28.2 28.6 29.1 29.0 
Prior MI , % ‡   38 33 23 17 15 
History of CHF, %  † 6 8 7 10 8 
History of Diabetes, % ‡ 14 26 25 26 31 
Severe concomitant non-cardiac 
disease, % ‡ 6 29 32 36 37 
Prior CABG, %  ‡ 11 12 14 14 16 
Smoking, % ‡      
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 Table 1.1 continued 
   Current 31 29 29 25 23 
   Former 40 38 40 41 40 
Ejection fraction, mean ‡ 58.0 55.3 53.1 51.9 52.2 
Primary Reason for 
Revascularization, %  ‡      
  Stable Angina 38 25 21 19 20 
     CCSC I/II 17 12 6 8 10 
     CCSC III/IV 20 12 6 6 5 
  Unstable Angina /Acute MI 58 66 72 69 68 
     Cardiogenic shock n/a 2 2 3 2 
     Thrombolytic therapy‡ 4 6 10 9 7 
  Asymptomatic CAD / Other 4 9 7 12 12 
Procedural details      
Procedural circumstance, % ‡      
   Elective 75 63 55 49 54 
   Urgent 19 24 31 38 32 
   Emergent 6 13 14 13 14 
Baseline significant lesions, mean ‡ 2.6 2.7 2.7 2.9 3.1 
Number of lesions attempted, % ‡      
    1 63 68 69 68 72 
    2 25 24 24 24 23 
    ≥ 3 12 8 8 8 5 
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 Table 1.1 continued 
Baseline vessel disease, % ‡      
    Single 48 46 47 40 36 
    Double 32 32 30 33 32 
    Triple 21 22 23 28 33 
Number of vessels attempted, % ‡      
    1 native vessel 77 84 83 83 81 
    2 native vessels 17 10 10 10 14 
    3 native vessels 2 0.6 0.7 0.9 0.3 
    Graft only 3 4 5 5 4 
    ≥ 1 native vessel and graft 1 1 1 0.7 1 
Overall balloon use, % ‡ 100 97 92 80 79 
Overall stent use, % ‡ n/a 70 85 94 95 
Gp IIb/IIIa inhibitors prior or during 
procedure, % ‡
n/a 25 34 55 37 
Clopidogrel and/or ticlopidine 24 
hours prior or during procedure, % ‡
n/a 52 43 65 85 
BMI: Body mass index, CCSC: Canadian cardiovascular society classification; MVD: multivessel 
disease; n/a: not available; Ptrend in characteristics across the cohorts: * ≤ 0.05, † ≤ 0.01, ‡ ≤ 0.001, 
assessed using Cochran Armitage test for 2-level categories and Jonckeheere-Terpsta test for continuous 
variables and nominal / ordinal categories  
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 Table 1.2: Characteristics of attempted lesions and angiographic outcome in the NHLBI-
sponsored PTCA (1985-86) and Dynamic (1997-2004) registries 
 
 
PTCA 
 
Dynamic Registry 
 
 
Registry 
 
Wave 1 
 
Wave 2 
 
Wave 3 
 
Wave 4 
 (N=3791) (N=2218) (N=1755) (N=1728) (N=1720) 
Location, % ‡      
  Right coronary artery  29 34 35 34 32 
  Left main  0.4 0.9 0.7 1 1 
  Left anterior descending  46 39 36 38 38 
  Left circumflex 21 22 22 22 24 
  Graft  3 5 6 5 5 
Diameter stenosis, % ‡      
  < 50% 2 2 2 1 0.2 
  50-70% 15 10 12 9 5 
  70-90% 37 31 35 39 49 
  90-99% 34 41 39 40 34 
  Total occlusion 2 16 13 11 12 
Lesion Characteristics      
  Evidence of thrombus ‡ 11 22 24 18 17 
  Calcified ‡ 11 30 27 24 27 
  Receives collaterals ‡ 21 14 14 10 10 
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 Table 1.2 continued 
  Supplies collaterals 8 6 4 4 10 
Final % stenosis, mean ‡ 33 12 9 6 5 
Angiographic success, %   81 94 95 95 96 
Complications, %      
  Dissection ‡ 3 12 5 2 3 
  Side branch occlusion 0.4 3 2 2 2 
  Abrupt closure (in lab) ‡ 3 2 1 0.3 0.2 
Ptrend in characteristics across the cohorts: * ≤ 0.05, † ≤ 0.01, ‡ ≤ 0.001, assessed using Cochran 
Armitage test for dichotomous variables and Jonckeheere-Terpsta test for continuous variables and 
nominal / ordinal categories 
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 Table 1.3: Trends in duration of hospital stay and discharge medications, among those 
alive at discharge, in the NHLBI-sponsored PTCA (1985-86) and Dynamic (1997-2004) 
registries 
 
PTCA 
 
Dynamic Registry 
 Registry 
 
Wave 1 Wave 2 Wave 3 Wave 4 
 (N=2397) (N=1527) (N=1228) (N=1194) (N=1258) 
Mean length of Stay, days ‡ 4.1 2.7 2.6 2.4 2.2 
Discharge Medication, %      
  Aspirin ‡ 84 94 94 95 97 
  ACE inhibitor ‡ 1 29 37 45 54 
  Beta blocker ‡ 26 66 72 77 81 
  Calcium channel blocker ‡ 78 30 21 17 14 
  Statins ‡ n/a 33 54 70 83 
  Digitalis 6 6 7 6 4 
  Diuretics ‡ 6 15 18 20 24 
  Long-acting nitrates ‡ 34 33 27 21 13 
  Ticlopidine ‡ n/a 70 23 1 1 
  Clopidogrel ‡ n/a n/a 61 92 95 
  Warfarin ‡ 4 5 6 9 8 
N/a: not available. Ptrend in characteristics across the cohorts: * ≤ 0.05, † ≤ 0.01, ‡ ≤ 0.001, 
assessed using Cochran Armitage test for dichotomous variables and Jonckeheere-Terpsta test 
for continuous variables and nominal / ordinal categories.  
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 Table 1.4: Risk of Death and Death / MI at one year for the NHLBI-sponsored 1997-2004 
Dynamic registry (reference: 1985-86 PTCA registry) 
 
Death (N=345) 
 
Death / MI (N=730) 
 
 
HR 
 
95% CI 
 
HR 
 
95% CI 
Unadjusted 
PTCA  Registry 
DR  Wave 1 
DR  Wave 2 
DR  Wave 3 
DR  Wave 4 
 
1.00 
1.53†
1.51†
1.43* 
1.57†
 
reference 
1.12-2.09 
1.09-2.09 
1.02-2.01 
1.14-2.15 
 
1.00 
0.96 
0.96 
0.88 
1.00 
 
reference 
0.78-1.18 
0.77-1.20 
0.70-1.11 
0.80-1.23 
Adjusted§
PTCA Registry 
DR  Wave 1 
DR  Wave 2 
DR  Wave 3 
DR  Wave 4 
 
1.00 
0.92 
0.96 
0.77 
0.89 
 
reference 
0.64-1.33 
0.66-1.40 
0.51-1.16 
0.60-1.32 
 
1.00 
0.67‡
0.68†
0.59‡
0.69†
 
reference 
0.53-0.85 
0.53-0.88 
0.45-0.78 
0.54-0.89 
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Table 1.4 continued 
P value: * ≤ 0.05, † ≤ 0.01, ‡ ≤ 0.001;   
§ Covariates included for adjusted estimates are listed below, by type of event: 
Death: Age<65, body mass index, smoking status, history of congestive heart failure, diabetes, 
hypercholesterolemia, primary reason for revascularization, procedural circumstances, severe 
non-cardiac comorbidities, multivessel disease, attempt of total occlusion and proximal left 
anterior descending artery disease, overall balloon use; Death/MI: Age >65 years, body mass 
index, history of congestive heart failure, diabetes, primary reason for revascularization, 
procedural circumstances, and attempt of lesions with evidence of thrombus, calcified, 
receiving collaterals or in vein grafts 
 
 Table 1.5: Risk of Early (≤30 days) and Late (31-365 days) repeat revascularization for the NHLBI-sponsored 1997-2004 
Dynamic Registry (reference: 1985-86 PTCA registry) 
 
Repeat PCI
 
CABG
 
CABG / Repeat PCI
Early (N=92)    Late (N=833) Early (N=243) Late (N=286) Early (N=333) Late (N=1016) 
 
 
HR 
 
95% CI 
 
HR 
 
95% CI 
 
HR 
 
95% CI 
 
HR 
 
95% CI 
 
HR 
 
95% CI 
 
HR 
 
95% CI 
Unadjusted 
  PTCA  
DR  Wave 1 
DR  Wave 2 
DR  Wave 3 
DR  Wave 4 
 
1.00 
2.43†
1.41 
2.34† 
2.15* 
 
reference 
1.32-4.48 
0.68-2.93 
1.22-4.51 
1.14-4.07 
 
1.00 
0.66‡
0.45‡
0.54‡ 
0.32‡
 
reference 
0.55-0.79 
0.36-0.56 
0.44-0.68 
0.25-0.41 
 
1.00 
0.26‡
0.23‡
0.13‡
0.25‡
 
reference 
0.18-0.40 
0.14-0.36 
0.07-0.24 
0.16-0.39 
 
1.00 
0.83 
0.68* 
0.38‡
0.22‡
 
reference 
0.61-1.11 
0.48-0.94 
0.25-0.59 
0.13-0.36 
 
1.00 
0.49‡
0.33‡
0.31‡
0.42‡
 
reference 
0.36-0.66 
0.22-0.48 
0.21-0.47 
0.30-0.59 
 
1.00 
0.66‡
0.48‡
0.47‡
0.29‡
 
reference 
0.56-0.78 
0.39-0.58 
0.40-0.60 
0.23-0.37 
Adjusted §
 PTCA  
DR  Wave 1 
DR  Wave 2 
DR  Wave 3 
DR  Wave 4 
 
1.00 
2.25†
1.29 
2.00* 
1.78 
 
reference 
1.22-4.16 
0.62-2.68 
1.04-3.87 
0.93-3.41 
 
1.00 
0.72‡
0.50‡
0.58‡
0.35‡
 
reference 
0.60-0.87 
0.39-0.62 
0.47-0.73 
0.27-0.45 
 
1.00 
0.23‡
0.21‡
0.11‡
0.22‡
 
reference 
0.15-0.34 
0.13-0.34 
0.06-0.22 
0.14-0.34 
 
1.00 
0.82 
0.67* 
0.37‡
0.19‡
 
reference 
0.61-1.10 
0.48-0.93 
0.24-0.58 
0.11-0.32 
 
1.00 
0.39‡
0.27‡
0.26‡
0.33‡
 
reference 
0.28-0.53 
0.18-0.41 
0.17-0.39 
0.23-0.47 
 
1.00 
0.72‡
0.52‡
0.52‡ 
0.31‡
 
reference 
0.60-0.85 
0.43-0.64 
0.42-0.64 
0.24-0.39 
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Table 1.5 continued 
HR: hazard ratio; CI: confidence interval, P value: * ≤ 0.05, † ≤ 0.01, ‡ ≤ 0.001.  
§ Covariates included for adjusted estimates are listed below, by type of event: 
Early Repeat PCI: Multivessel disease (MVD) and primary reason for revascularization; Late Repeat PCI: Age >65 years, primary reason for 
revascularization, evidence of thrombus, number of lesions and vessels attempted; Early CABG: Previous CABG, multivessel disease, circumstances of 
procedure, number of lesions attempted, total occlusion attempted, and proximal LAD lesion; Late CABG: History of Diabetes, MVD, and proximal 
LAD lesion; Early Repeat PCI/CABG: MVD, primary reason for revascularization, procedural circumstances, calcified lesion, total occlusion 
attempted, and proximal LAD lesion attempted; Late Repeat PCI/CABG: Age > 65 years, history of diabetes, MVD, primary reason for 
revascularization, evidence of thrombus, number of lesions attempted, proximal LAD lesion attempted, and vein graft attempted 
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* Ptrend <0.001, assessed using Cochran Armitage test  
Figure 1.1: Trends in in-hospital outcomes in the NHLBI-sponsored PTCA (1985-
86) and Dynamic (1997-2004) registries 
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Figure 1.2: Cumulative (Kaplan Meier) event rates for Death and Death/MI in the 
NHLBI-sponsored PTCA (1985-86) and Dynamic (1997-2004) registries at one year 
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 (A) Early (≤ 30 days) and Late (31-365 days) CABG  
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(B) Early (≤ 30 days) and Late (31-365 days) Repeat PCI 
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Figure 1.3: Cumulative (Kaplan Meier) event rates for early (≤ 30 days) and late 
(31-365 days) CABG (A) and repeat PCI (B) in the NHLBI-sponsored PTCA (1985-86) and 
Dynamic (1997-2004) registries 
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 2.1 ABSTRACT 
Evolution of percutaneous coronary intervention (PCI) with associated impact on clinical 
outcomes is well-documented. Our objective is to document temporal trends in post-procedural 
symptoms in patients sequentially enrolled in the NHLBI-sponsored Dynamic Registry (N in 
waves-1:2010, 2:1633, 3:1512, 4:1846). At 1-year follow-up, the percentage of consecutive 
patients (N: 6246) reporting angina of any severity in the past 6 weeks decreased from 24% in 
wave 1 to 20% in wave 4 (Ptrend:<0.001). Evidence suggestive of interaction with PCI era was 
seen with large reduction in angina rates for patients with prior MI, diabetes, lack of initial 
procedural success, procedural use of anti-platelet agents and those discharged on ≥ 2 medication 
classes (beta blockers, long-acting nitrates, calcium-channel blockers, ACE-inhibitors). In 
contrast, difference in angina rates by history of prior PCI widened over time.  Risk of post-PCI 
angina was lower for recent cohorts, even after adjusting for age, sex, race, primary reason for 
PCI, prior bypass or PCI, smoking status, comorbidities, repeat PCI, use of stent and ≥ 2 
medication classes [relative risk (95% CI): 1.0 (0.9-1.1), 0.7 (0.7-0.8), 0.8 (0.7-0.9) for waves 
2,3,4, compared to wave 1]. In the drug-eluting stent era (wave 4), significant predictors of post-
PCI angina included female sex, prior bypass, prior or repeat PCI, and one-year MI. In 
conclusion, favorable temporal trends are seen in prevalence and risk of post-PCI angina, 
paralleling the evolution of the field in the last three decades. In contemporary practice, specific 
subgroups remain at high risk for symptoms and warrant closer attention.  
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 2.2 BACKGROUND  
Symptom relief and prolongation of life remain the primary goals of cardiovascular therapy. 
Percutaneous coronary intervention (PCI) has evolved rapidly in the past two decades and while 
the associated favorable impact on clinical success (high procedural success rates and reduced 
need for repeat revascularization) has been well-documented 24, 27, 43, there are few reports on the 
impact on post-procedural symptoms. More importantly, given the lack of demonstrable 
mortality benefit, there is an important need to focus on symptom-related patient outcomes 
following revascularization. The NHLBI-sponsored Dynamic registry enrolled consecutive 
patients undergoing PCI in 4 sequential waves from 1997 to 2004 24, 44. The registry represents 
significant phases in PCI evolution and can, therefore, provide insight into prevalence of post-
PCI angina over time. The purpose of this report, therefore, is to 1) document temporal trends in 
patient-reported one year post-PCI angina and, 2) identify significant predictors of angina in 
contemporary practice (wave 4). 
2.3 METHODS 
2.3.1 The NHLBI-sponsored 1997-2004 Dynamic Registry 
Consecutive patients undergoing PCI were sequentially enrolled in recruitment waves: Wave 1: 
1997-98, Wave 2: 1999, Wave 3: 2001-2002, and Wave 4: 2004; each cohort was enriched 
(oversampled) with women and minorities 24, 44. Baseline information on patient and procedural 
characteristics were ascertained by research coordinators trained in data collection. Written 
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 informed consent was obtained from participants at baseline for enrollment and follow-up 
contacts. Patients were contacted by telephone, mail or during clinic visits, at one year of follow-
up, and information on angina and medication use, in the past 6 weeks, was obtained. 
Hospitalizations for angina, myocardial infarction (MI), bypass surgery (CABG), and repeat PCI 
over one year were also recorded. The study protocol was approved by the Institutional Review 
Board of the University of Pittsburgh and those of all sites involved.  
Stable angina was defined as pain precipitated by exertion and relieved by rest and/or 
sublingual nitroglycerin, with no change in pattern or severity within 6 weeks before intervention 
(baseline) or in the previous 6 weeks (follow-up). Unstable angina was defined as either pain 
presenting at rest, or exertional pain of at least Canadian Cardiovascular Society (CCS) Class III 
that began or increased in severity at least one CCS Class in the 2 months before intervention of 
follow-up. Acute MI, in the first 2 waves, was defined by the documented presence of ≥2 of the 
following criteria: clinical symptoms, enzyme-level elevations, new wall-motion abnormalities, 
and ≥2 serial electrocardiogram tracings showing changes from baseline or serially in ST-T 
and/or new Q waves in ≥2 contiguous leads; for waves 3 and 4, diagnosis of MI was based on 
either biochemical evidence of necrosis or serial ECG changes. Attempted lesions were 
considered complex if ≥ 1 of the following features were present: evidence of thrombus, 
calcified, at bifurcation, chronic total occlusions (occlusions in patients undergoing PCI for 
reasons other than MI), and ostial lesions 30. 
Overall 8788 patients were enrolled in the registry and ~ 90% consented for follow-up.  
The present analysis excludes 297 patients who died within one year (% by waves: 3.5, 5.3, 5.0, 
2.2; Ptrend: 0.07) and 131 patients with no follow-up information (% by waves: 1.1, 1.4, 3.6, 1.5; 
Ptrend: 0.02). To ensure generalizability, prevalence rates at follow-up were calculated using 
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 consecutive patients only (N=6246) so that the enriched sample of women and minorities, 
recruited after the registry was closed to white men, were not included. Risk of follow-up angina 
for all waves, as well as significant predictors specific to wave 4 only (the most current wave) 
was based on all patients (N=7001) including the enriched subset. 
2.3.2 Statistical Methods 
Follow-up angina rates in consecutive patients are summarized by waves of enrollment and 
temporal trends – overall and by baseline characteristics - assessed using the Cochran-Armitage 
test for dichotomous variables 28 and the Jonckeheere-Terpsta test for continuous and 
nominal/ordinal variables 29. In subgroup analyses, the possible differential effect of patient and 
procedural characteristics on the occurrence of angina over time was modeled using interaction 
term with recruitment wave in logistic regression models; P≤ 0.15 was considered suggestive of 
interaction. Relative risks (unadjusted and adjusted) of post-PCI angina, with wave 1 as the 
referent category, were estimated using generalized linear models specifying the binomial 
distribution and log link function (PROC GENMOD in SAS). For multivariate adjustment, 
baseline factors that significantly differed across the cohorts (Ptrend ≤ 0.05) and were also 
associated with follow-up angina (P ≤ 0.10) were considered. For the final model, recruitment 
wave was included with a stepwise selection (Pentry ≤ 0.10, Pstay ≤ 0.05) method used to select 
other significant covariates. To assess the impact of missing angina information, sensitivity 
analyses were performed by assigning symptomatic status to patients 1) alive but missing 
information and, 2) who died over one year. 
Significant predictors of post-PCI angina, in contemporary practice (wave 4), were 
identified using only baseline symptomatic patients (primary reason for index PCI: stable or 
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 unstable angina or acute MI), for comparability with previous report 45.  Sequential models were 
fit using stepwise selection methods and log binomial regression analysis.  The first adjusted 
model included baseline patient and procedural characteristics.  The second adjusted model 
included Model 1 variables and statistically significant in-hospital and one-year characteristics, 
including intercurrent adverse events and repeat revascularization.  All analyses were performed 
with SAS version 9.1 (SAS Institute Inc, NC). 
2.4 RESULTS 
Compared to 1997-98 (wave 1), patients in the latter waves were older, had more comorbidities 
(hypertension, diabetes and severe non-cardiac conditions) and prior revascularization (PCI or 
CABG) (Table 2.1). Although number of diseased vessels / lesions, at baseline, increased over 
time, procedural attempts more often involved single vessels / lesions. Overall stent use 
increased over time (66% to 93%), with 75% of wave 4 patients receiving a drug-eluting stent.  
Over time, there was more frequent use of glycoprotein IIb/IIIa inhibitors (wave 1: 23%, wave 2: 
32%, wave 3: 52%, wave 4: 35%, Ptrend: <0.001), and antiplatelets (ticlopidine or clopidogrel, 
wave 1: 51%, wave 2: 42%, wave 3: 66%, wave 4: 86%, Ptrend: <0.001). Procedural success was 
also achieved more often over time with fewer complications and in-hospital adverse events. 
At discharge, aggressiveness of medical therapy increased over time.  Specifically, more 
patients were prescribed aspirin (wave 1: 94%, wave 2: 94%, wave 3: 95%, wave 4: 97%, Ptrend: 
<0.001), ticlopidine or clopidogrel (wave 1: 67%, wave 2: 82%, wave 3: 94%, wave 4: 96%, 
Ptrend: <0.001), beta-blockers (wave 1: 65%, wave 2: 71%, wave 3: 77%, wave 4: 81%, Ptrend: 
<0.001), angiotensin converting enzyme (ACE) inhibitors(wave 1: 29%, wave 2: 34%, wave 3: 
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 46%, wave 4: 56%, Ptrend: <0.001) and lipid lowering medications (wave 1: 46%, wave 2: 60%, 
wave 3: 76%, wave 4: 87%, Ptrend: <0.001). However, prescription of calcium channel blockers 
and long acting nitrates decreased from 36% and 33% respectively in wave 1 to 15% in wave 4 
(Ptrend:<0.001 for both).  
2.4.1 Angina in the past 6 weeks at one – year of follow-up 
When contacted at one year, fewer patients, over time, reported angina of any severity in the past 
6 weeks – both in the overall cohort (24% in wave 1 to 20% in wave 4, Ptrend: <0.001) and among 
symptomatic patients (Figure 2.1). Additionally, angina rates at 1-year were higher among 
patients who had undergone index PCI for stable angina, compared to other reasons. Among 
patients who reported angina at one year (Table 2.2), there was an indication of more frequent 
episodes of angina (i.e. 3 or more times per day) in the latter recruitment waves (Ptrend: 0.01). 
While 1-year reported use of aspirin, beta-blockers, ACE inhibitors, lipid lowering medications 
and antiplatelet therapy increased over time, use of calcium channel blockers and long acting 
nitrates decreased (Ptrend for all: <0.001), the need for repeat revascularization (both PCI and 
CABG), following index PCI, decreased significantly across the waves (Table 2.2).  
2.4.2 Temporal trends in post-PCI angina within baseline characteristics  
The overall decreasing trend in patient-reported angina rates over time was evident in most 
subgroups classified by patient and procedural characteristics (Table 2.3).  However, there was 
evidence suggestive of interaction (differential effect) with PCI era for several characteristics.  
This included evidence of a large reduction in rates of angina over time for patients with prior 
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 MI, diabetes, lack of initial procedural success, procedural use of anti-platelet agents and those 
discharged on ≥ 2 medication classes (beta blockers, long-acting nitrates, calcium-channel 
blockers, ACE-inhibitors). In contrast, difference in angina rates by history of prior PCI widened 
over time.  
2.4.3 Risk of post-procedural angina: 
Compared to wave 1, the unadjusted risk of follow-up angina was 4-28% lower for more recent 
waves, with statistical significance achieved for waves 3 and 4; adjustment for cohort differences 
did not alter the pattern (Figure 2.2). Secondary univariate analyses in only successful 
procedures (angiographic and procedural) or those in whom symptoms (stable or unstable angina 
or acute MI) were the primary reason for index PCI, showed similar trend.  Of note, overall use 
of stents (vs no stent) was univariately associated with reduction in follow-up angina risk in all 4 
waves (Relative risk in waves 1, 2, 3, 4: 0.77, 0.79, 0.63, 0.62, P≤ 0.05 for all). 
Patients alive but missing angina information at follow-up were more often younger 
(65% vs 54%, P: 0.02) with multivessel disease (64% vs 59%, P: 0.34), had undergone 
procedures mostly for AMI (29% vs 24%, P: 0.88), with fewer calcified (51% vs 54%, P: 0.06) 
and more ostial lesions (15 % vs 10%, P: 0.06);  procedural (93% vs 97%, P: 0.01) and total 
angiographic (88% vs 94%, P: <0.01) success was achieved less frequently. However, results of 
the sensitivity analysis were similar to that in the overall cohort (relative risk of angina for waves 
2, 3, 4 with wave 1 as reference: 0.97, 0.81, 0.81; P ≤ 0.001 for waves 3 and 4).    
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 2.4.4 Factors associated with follow-up angina in contemporary practice 
Of the 1846 survivors in wave 4, 1596 had undergone index PCI for angina (stable /unstable) or 
AMI. Among the baseline independent predictors of 1-year angina, age > 65 years was 
associated with decreased risk and female gender, history of CHF, peripheral vascular disease 
and prior CABG/ PCI were associated with increased risk of follow-up angina (Table 2.4). 
Patients discharged on ticlopidine or clopidogrel were less likely to report angina at one year 
(RR: 0.74, P:0.06) whereas those hospitalized for MI or repeat PCI following the index 
procedure showed a 1.5-fold increase in risk of angina at 1-year.  
Although overall stent use, which was near universal in wave 4, was not an independent 
predictor, it was univariately associated with reduced risk of post-PCI angina (relative risk (95% 
CI):0.623 (0.40-0.96)). However, when stents were used in this cohort of symptomatic patients 
(angina or acute MI), drug-eluting stents were associated with increased, albeit non-significant, 
unadjusted risk (relative risk (95% CI):1.16(0.89-1.50))   
2.5 DISCUSSION 
This report documents favorable temporal trends in patient-reported post-PCI angina in a 
prospective multicenter registry, spanning a decade of clinical practice. Specifically, prevalence 
and risk of post-procedural angina has decreased over time and parallels technological evolution 
and improved use of secondary pharmacotherapy in the field.  
The NHLBI-sponsored Dynamic registry cohorts primarily represent evolution in PCI 
since its initial use 8, with routine and increasing use of stents (bare metal and coated), 
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 antiplatelet regimen, and aggressive secondary CAD management. Indeed, this evolution has 
resulted a proven reduction in the need for repeat revascularizations, even in a heterogeneous 
patient (and lesion) population 24, 46, 47. However, with the lack of demonstrable mortality benefit, 
the true value of PCI, especially from a patient’s perspective, lies in symptom relief. Although 
numerous reports have demonstrated favorable impact of PCI on post-procedural symptoms 45, 26, 
48;48, 49, their findings were from specific phases of PCI advancement. The current report is 
unique in that it is prospective, spans over a decade of real world clinical practice and reflects 
improvements in prevalence of post-PCI angina. 
The association of PCI era with post-PCI angina could be attributed to a combined impact 
of new technology, adjunct therapy, and more aggressive secondary management. In the early 
stent era, Holubkov et al 45 showed that overall stent use was associated, although not 
independently, with fewer symptoms. Similarly, in the present report, stent use was univariately 
associated with reduced risk of follow-up angina, both overall and in individual cohorts. 
Additionally, in keeping with recommended guidelines 47, secondary management with aspirin, 
antiplatelets, and lipid-lowering medications is more frequently pursued. Even with the overall 
reduction in anti-anginal mediation use, we see an increase in beta-blocker use with a contrasting 
decrease in nitrates and calcium-channel blockers. Although information on baseline use or 
reason for follow-up use was not available in this registry, this is a likely reflection of the 
beneficial effects of beta-blockers on all-cause mortality and morbidity 50. Interestingly, 
compared to wave 1, risk of angina was significantly reduced only for the two most recent 
waves. One possible explanation is a likely similarity between the first two waves with the latter 
cohorts witnessing more variety and use of technology (intracoronary radiation, atherectomy 
devices, drug-eluting stents) and post-procedural management, in a widened patient and 
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 procedural profile. On other hand, PCI, over time, has been increasingly applied to sicker 
patients and our original analyses included only survivors with one year information. Risk 
estimates from sensitivity analyses, however, showed little variation.  
Post-revascularization angina, in spite of reduced prevalence, remains a matter of 
concern, especially since PCI is aimed at targeting ischemia-causing ‘culprit’ lesions. Some 
important factors that may result in post-PCI symptoms include failed index procedure 
(restenosis or residual disease) or new or progressed disease. While technological advancements 
have dramatically reduced restenosis rates 12, residual multivessel or left main disease has been 
shown to be an independent predictor of follow-up angina 45. Therefore, given the diverging 
trends in treatment strategy (fewer vessels attempted compared to number of vessels diseased) 
over time 24, 27, one might have expected an increase in angina rates over time. However, the 
observed reverse trend is encouraging and may be attributed to safer, more successful procedures 
followed by aggressive secondary management.  Atherosclerosis is a chronic process and disease 
progression, though expected, cannot be adequately predicted, even in patients undergoing PCI40. 
This further underscores the need for continued aggressive risk factor modification. The latter 
may also influence outcomes in specific co morbid characteristics and to this end, the apparent 
substantial reduction in post-PCI angina among patients with diabetes deserves mention. This 
marked improvement lends support to the favorable trends seen in other in-hospital and one year 
outcomes observed in this subset 51. 
2.5.1 Predictors of Angina in contemporary practice 
Post-procedural evaluation, in real world practice, is more often triggered by symptoms and 
identifying significant predictors could, therefore, serve as a ‘susceptibility’ index. This is 
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 especially important in contemporary practice, given concerns of cost-effectiveness of coated 
stents 52, 53. Factors independently predictive of increased risk of follow-up angina, in the DES-
era, were female sex, age < 65 years, prior revascularizations and intercurrent hospitalizations for 
MI or repeat PCI. In spite of the reported gender-specific improvement in in-hospital and long-
term outcomes following PCI 54,55,56, female gender, also associated with under-use of evidence-
based medications 57 , remains a significant risk factor for post-procedural symptoms 45, 58. In an 
era of improved success and single-digit restenosis rates, patients with prior PCI and those 
requiring repeat PCI, may be representative of a unique subset of alleviated disease burden. The 
differential impact of these characteristics on post-PCI angina further supports this notion, and 
warrants closer attention. Additionally, in light of emerging reports of off-label use 16 and 
adverse events with drug-eluting stent use 59, 60, the increased risk of angina, though non-
significant, in this cohort of symptomatic patients, needs further exploration. 
The NHLBI-sponsored Dynamic registry relies on voluntary participation and majority of 
the clinical sites are moderate-large volume centers, limiting universal generalizability of the 
findings. Lack of information on baseline symptom profile limits ability to assess benefit from 
the initial procedure.  Angina, the outcome of interest, is highly subjective and also influenced by 
psychosocial aspects 58,61.  Data on these and recommended lifestyle modifications were not 
routinely collected. Further analysis is underway to evaluate patient-reported quality of life, as 
means to validate self-reported symptom status, as well as temporal trends in supplemental 
therapy used to achieve it in this cohort.  
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 2.6 CONCLUSION  
Our report, from a large prospective, multicenter registry, documents favorable temporal trends 
in prevalence and risk of post-PCI angina in a decade of real world clinical practice. In spite of 
this overall trend, women and patients with prior or repeat PCI continue to remain at high-risk 
for post-procedural symptoms. 
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 Table 2.1: Baseline patient, procedural and discharge characteristics of patients alive at 1 
year following PCI in the NHLBI-sponsored 1997-2004 Dynamic Registry 
  Dynamic Registry Waves 
 1 2 3 4 
Total patients 1793 1417 1379 1657 
Patient characteristics     
Age >65 years † 42.6 46.4 49.5 46.4 
Female 31.2 30.6 32.7 28.2 
White  † 88 90.8 89.3 84.9 
Prior CABG ‡ 16 18.5 18.6 20.4 
Prior MI ‡ 38.5 31.4 26.1 26.7 
Prior PCI * 29.6 29.1 32.3 32.1 
Severe concomitant non-cardiac disease ‡ 27.9 32 36.4 35.4 
     Cerebrovascular 5.2 6.4 5.6 7.9 
     Peripheral artery disease 7 6.4 8.2 8.4 
     Pulmonary disease 6.2 8.7 7.6 6.7 
     Cancer 6 6.4 8.1 7.3 
     Renal failure /Insufficiency 2.8 3.7 5.6 7.3 
     Other 7.9 10.3 15 13.9 
History of Diabetes ‡ 25.1 25.5 27 32.1 
History of CHF 8.5 7.5 10.1 7.9 
History of Hypertension ‡ 58.8 62 71.8 76.5 
Smoking †     
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 Table 2.1 continued     
    Never 31.9 30 34.5 38 
    Former 43.8 45.7 43.9 41.5 
    Current 24.3 24.3 21.6 20.5 
Mean Ejection fraction § ‡ 55.9 54.1 52.7 52.2 
Baseline Vessel Disease ‡     
    Single 42.8 44.4 38 34.4 
    Double 32 30.4 31.8 32.7 
    Triple 23.5 25.1 30.2 32.9 
Graft body disease 11.4 12.8 13.2 14.7 
Total occlusion (native vessels or graft) 35.5 34.1 35.5 38.9 
Proximal LAD disease 32.7 35.9 32.5 35.5 
Mean significant lesions † 2.8 2.9 3.1 3.1 
Procedural data     
Primary reason for index PCI ‡     
    Stable Angina 26.7 21.3 20.4 23.1 
    UA / AMI 64.2 71.5 70 63 
    ACAD /Others 9 7.2 9.7 13.9 
Circumstances of index PCI ‡     
    Elective 67.4 57.9 51.4 58 
    Urgent 23.3 32.3 38.1 31.3 
    Emergent 9.3 9.9 10.4 10.7 
# of lesions attempted †     
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 Table 2.1 continued     
    One 67.3 69.2 69.5 72.1 
    ≥ 2 or more 32.7 30.8 30.5 27.9 
# of vessels attempted †     
    1 native vessel only 83.1 82.6 82.2 79.2 
    2 -3 native vessels only 9.2 9.2 9.7 12.8 
    Graft +/- native vessels (s) 7.6 8 8.1 8 
Complex lesions (evidence of thrombus, ostial , 
bifurcation, calcified, chronic total occlusions) ‡ 61.6 59.6 53.9 53.9 
Ulcerated 15.3 15.7 15.2 15 
Proximal LAD attempted 17.3 18.6 15.6 15.5 
Gp IIb/IIIa inhibitors 24 hrs prior /during PCI ‡ 23 32.4 52.4 34.5 
Ticlopidine/Clopidogrel < 24hrs/during PCI ‡ 51 42.1 66.1 86.3 
Device use     
    Overall balloon use ‡ 97.4 92 74.8 75.4 
    Overall stent use ‡ 66.5 80.7 88.3 93.4 
In-hospital outcome and discharge data     
Overall total angiographic success ‡ 93 93.1 94.8 95.5 
Procedure success * 96.8 97 97.7 97.6 
Any in-hospital complication (dissection, side 
branch occlusion, abrupt closure, slow flow, 
embolization) ‡ 18.9 9.5 7.3 7.6 
MI (in-hospital) 2.6 2.9 1.9 2.4 
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 Table 2.1 continued     
CABG (in-hospital) 1.1 1.1 0.6 0.8 
Major entry site complication † 2.7 3.8 2.9 4.7 
Medications at discharge      
   Aspirin ‡ 94.2 93.6 95 96.9 
   Beta-blockers ‡ 65.3 70.8 77 81.2 
   Long-acting nitrates ‡ 33.4 27.3 24.8 15.4 
   ACE-Inhibitors ‡ 28.6 34.3 45.9 55.7 
   Calcium channel blockers ‡ 35.9 27.3 20.7 15.1 
   Lipid lowering medications ‡ 45.5 60 76.1 87.2 
   Digitalis ‡ 6.5 6.3 5 3.4 
   Diuretics ‡ 14.1 17.8 20.7 23.4 
   Warfarin † 5.5 6.1 7.6 7.5 
   Low-molecular-weight heparin** 1.3 1.1 0.6 0.7 
   Ticlopidine /Clopidogrel ‡ 67.1 81.5 94 96.1 
Ptrend using Cochran-Armitage test for dichotomous variables and JT test for continuous & 
ordinal variables: * ≤0.10, ** ≤ 0.05, † ≤ 0.01, ‡ ≤0.001; § 33% of data missing 
ACE: Angiotensin-converting enzyme inhibitors, CHF: Congestive heart failure, CABG: 
coronary artery bypass grafting, LAD: Left anterior descending artery, MI: Myocardial 
infarction, PCI: Percutaneous coronary intervention 
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 Table 2.2: Temporal trends in post-procedural angina and related characteristics at one 
year follow-up in the NHLBI-sponsored 1997-2004 Dynamic Registry 
  Dynamic Registry Waves 
 
1 
(1997-98) 
2  
(1999) 
3 
(2001-2002) 
4  
(2004) 
Total Patients 1793 1417 1379 1657 
Presence of Angina in past 6 weeks ‡ 24.3 22.3 17.9 20 
Severity of Angina (among those with angina)     
   Stable CHC I/II Angina 54.5 54.2 59.5 58.6 
   Stable CHC III/IV Angina 20.5 20.8 23.2 12.9 
   Unstable Angina /AMI 25.1 25 17.3 28.5 
Frequency of Angina  
(among those with angina) †     
   3 or more times/day 4.3 7.7 6.3 9.6 
   1 to 2 times/day 13 10 13.5 13 
   Several times/week 30.9 31.4 38.8 31.2 
   Once/week or less 51.9 50.8 41.4 46.3 
Angina Status and use of Long-acting nitrates ‡     
   No Angina, No nitrates 59.5 65.1 69.4 71.2 
   No Angina, Nitrates used 15.7 11.7 11.9 8 
   Angina 24.3 22.4 17.8 20 
Medication use in the past 6 weeks       
   Aspirin ‡  85 84.9 84.9 89.9 
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Table 2.2 continued     
   Ticlopidine /Clopidogrel § ‡  1.7 3.8 16.9 59.8 
   Lipid lowering medications ‡  56.8 66.3 76.3 82.8 
   ACE-Inhibitors ‡  28.1 33.2 45.5 48.6 
   Beta-blockers ‡  60 65.4 70.3 75.5 
   Long-acting nitrates ‡  27.1 21.1 17.6 13.2 
   Calcium channel blockers ‡  29.8 24.6 21.3 16.4 
   Sublingual NTG ‡  76 67.4 63.8 61.3 
   Warfarin* 5.5 5.8 7.3 7.1 
   Angiotensin receptor blocker ‡ 1.9 4.3 5.4 12.5 
   AHM ‡ 7.7 6.8 8.9 10.6 
   Diuretics ‡ 20.1 21.5 24.1 25.8 
   Digitalis ‡  7.2 6 5.5 4.1 
Hospitalizations over 1 year     
   Angina ‡ 19.3 17.5 12.5 13.9 
   MI 5.2 5.4 4.8 4.5 
   Repeat PCI ‡ 16 12.9 12.2 9.5 
   CABG ‡ 6.9 6.2 4 2.5 
Ptrend using Cochran-Armitage test for dichotomous and JT test for ordinal variables:* ≤ 0.05, † ≤ 
0.01, ‡ ≤ 0.001; § Information on 1-year Clopidogrel use not routinely collected in Waves 2 and 3; 
ACE: Angiotensin-converting enzyme inhibitors, NTG: Nitroglycerin, AHM: Vasodilators/other anti-
hypertensive medications, MI: Myocardial infarction, PCI: Percutaneous coronary intervention, 
CABG: coronary artery bypass grafting 
 
 Table 2.3: Prevalence of one-year post-procedural angina within baseline and in-hospital characteristics in the NHLBI-
sponsored 1997-2004 Dynamic Registry 
 Waves of the Dynamic registry  
 Overall     
  
ears             
1 2 3 4 Ptrend* P ** 
 Total 
(N=6246) 
Angina 
(%) 
Total 
(N=1793)
Angina 
(%) 
Total 
(N=1337)
Angina 
(%) 
Total 
(N=1377) 
Angina 
(%) 
Total 
(N=1641)
Angina 
(%) 
Age > 65 y
  Yes              
             
Sex             
             
             
             
             
             
 MI             
              
             
             
2872 19.3 764 21.1 657 22.2 682 16.3 769 17.7 0.02 1
  No 3374 23.2 1029 26.7 760 23 697 19.4 888 22.1 0.004
  Male 4334 20.1 1233 22.7 983 21.6 928 16.5 1190 19 0.003 0.8
  Female 1912 24.3 560 27.9 434 25.1 451 20.6 467 22.7 0.02
Race
  White 5504 20.8 1578 24 1287 22.2 1232 16.5 1407 19.5 <0.001 0.36
  Non-whites 742 26 215 26.5 125 27.2 147 28.6 246 23.2 0.45
Prior
  Yes 1908 24.8 684 28.7 439 26.2 353 19.8 432 21.3 0.001 0.1
  No 4237 19.8 1091 21.5 957 21 1000 17.1 1189 19.4 0.07
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 Table 2.3 continued             
BG             
              
             
PCI             
              
              
             
etes             
              
             
HF             
              
             
           
              
             
Prior CA
  Yes 1141 29 286 31.2 262 30.5 256 24.6 337 29.4 0.4 0.18
  No 5099 19.7 1503 23.1 1155 20.9 1123 16.3 1318 17.6 <0.001
Prior 
  Yes 1919 27.1 528 29.2 413 27.9 446 24.4 532 26.5 0.21 0.14
  No 4317 18.8 1257 22.2 1004 20.5 933 14.7 1123 17 <0.001  
Severe Concomitant Non-Cardiac Disease 
  Yes 2034 23 497 25 452 27.2 501 18.4 584 22.1 0.04 0.7
  No 4185 20.5 1284 24 962 20.5 875 17.5 1064 18.9 0.001
History of Diab
  Yes 1707 23.4 443 29.8 360 25 372 19.4 532 19.7 <0.001 0.03
  No 4505 20.6 1321 22.6 1053 21.9 1007 17.3 1124 20.2 0.03
History of C
  Yes 522 25.5 152 26.3 106 24.5 137 24.8 127 26 0.94 0.24
  No 5625 21 1628 24.1 1305 22.5 1220 17.1 1472 19.4 <0.001
History of Hypertension   
  Yes 4151 22.5 1039 25.6 874 25.5 980 18.7 1258 20.7 <0.001 0.92
  No 2034 19.1 728 22.4 524 17 382 16 385 17.7 0.02  
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 Table 2.3 continued             
king             
             
             
             
ease             
              
sion             
              
             
ease             
              
             
PCI             
             
              
Smo
   Never 1978 21.4 546 23.4 398 21.9 435 19.3 599 20.7 0.19 0.61
   Ever (current + former) 3900 21.6 1168 24.8 929 23.1 826 17.8 977 19.5 <0.001  
Multivessel disease
   Yes  3742 22.8 1026 25.6 787 25 853 18.9 1076 21.6 0.03 0.68 
   No 2482 19.4 767 22.6 629 19.7 523 16.3 563 17.6 0.01
Graft body dis
   Yes 812 30.4 205 31.2 181 34.3 182 26.9 244 29.5 0.41 0.34
   No 5434 20 1588 23.4 1236 21 1197 16.5 1413 18.4 <0.001  
Any total occlu
   Yes 2254 24.5 637 27.3 483 26.3 489 20.3 645 23.7 0.04 0.5
   No 3992 19.6 1156 22.7 934 20.8 890 16.5 1012 17.7 0.001
Proximal LAD dis
   Yes 2131 22.5 586 23.2 508 27.6 448 18.8 589 20.2 0.03 0.82
   No 4115 20.8 1207 24.9 909 19.9 931 17.4 1068 19.9 0.001
Reason for index 
   Stable Angina 1445 24.6 479 27.4 302 25.8 281 20.3 383 23.5 0.08 -
   Unstable Angina / AMI 4172 22.1 1151 24.7 1013 23.3 964 18.6 1044 21.4 0.01 0.79 
   ACAD /Other 627 9.1 162 13 102 6.9 133 7.5 230 8.3 0.16 0.92
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 Table 2.3 continued             
             
             
             
             
pted             
              
             
pted             
              
             
             
pted             
             
             
             
             
Procedural Circumstances
  Elective 3698 21.5 1208 24.8 820 22 709 17.9 961 19.6 0.001 -
  Urgent 1918 21.9 417 24.7 457 23.6 526 19.6 518 20.5 0.05 0.40
  Emergent 627 19.1 166 20.5 140 23.6 144 11.1 177 20.9 0.51 0.65
# Vessels attem
 1 5104 20.9 1489 24.1 1170 21.9 1132 17.3 1313 19.4 <0.001 0.47
  ≥ 2 (native +/- graft) 1132 23.5 301 25.3 242 25.6 245 20.4 344 22.7 0.27
# Lesions attem
  1 4333 21.6 1205 25.6 937 22 957 18.4 1194 19.8 <0.001 0.25 
  ≥ 2 1903 20.8 585 21.7 435 23.7 420 16.7 463 20.7 0.25
Complex lesions attempted (bifurcation, calcification, ostial, chronic total occlusions) 
  Yes 3516 20.8 1105 22.7 790 22.5 737 17.5 884 19.5 0.01 0.52
  No 2632 22 688 26.9 547 21.9 640 18.3 757 20.6 0.002
Proximal LAD attem
  Yes 1044 19.2 310 17.4 262 26.3 215 15.8 257 16.7 0.33 0.56
  No 5192 21.8 1480 25.7 1150 21.7 1162 18.2 1400 20.6 <0.001
Any in-hospital complication (dissection, side branch occlusion, abrupt closure, slow flow, embolization) 
  Yes 699 22.5 338 25.2 134 20.9 101 17.8 126 20.6 0.15 0.87
  No 5547 21.2 1455 24.1 1283 22.8 1278 17.8 1537 20 <0.001
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 Table 2.3 continued             
 use             
             
 use             
             
             
             
             
             
             
             
Overall Balloon
  Yes  5331 21.1 1742 24.3 1303 22.9 1031 15.8 1250 19.2 <0.001 0.2 
  No 915 23 46 26.1 114 20.2 348 23.9 407 22.6 0.92
Overall Stent
  Yes  5100 20 1192 22.6 1144 21.4 1217 17 1547 19.4 0.01 0.39 
  No 1146 27.4 601 27.8 273 27.8 162 24.1 110 29.1 0.79
Procedural use of Gp IIb/IIIa Inhibitors 
  Yes 2165 19.5 412 21.1 459 22.4 723 17.8 571 18 0.07 0.93
  No 4081 22.4 1381 25.3 958 22.8 656 17.8 1086 21.1 0.002
Procedural use of Ticlopidine / Clopidogrel 
 Yes 3853 20.6 914 23 597 21.9 912 17.5 1430 20.4 0.07 0.05
  No 2393 22.7 879 25.7 820 23.2 467 18.4 227 17.6 0.001
Overall Angiographic Success 
  None /Partial 370 24.9 126 28.6 98 27.6 71 18.3 75 21.3 0.12 0.51 
  Total 5866 21.1 1664 24 1314 22.2 1306 17.8 1582 20 0.001  
Procedure Success (partial or total angiographic success without Q-wave MI/Emergency CABG) 
  Yes  6066 21.3 1733 24 1369 22.4 1346 17.8 1618 20.2 0.001 0.13 
  No 170 24.7 57 33.3 43 25.6 31 19.4 39 15.4 0.03
 57
  58
            
irin             
             
             
             
             
           
             
            
            
Table 2.3 continued 
Asp
  Yes 5928 21.1 1689 23.9 1325 22.2 1308 17.9 1606 20 0.001 0.25
  No 315 25.7 104 30.8 91 29.7 69 15.9 51 21.6 0.05
Ticlopidine / Clopidogrel
  Yes 5246 20.5 1203 22.7 1155 22.3 1296 17.7 1592 19.7 0.01 0.84
  No 1000 26.2 590 27.6 262 24.1 83 20.5 65 29.2 0.46  
Lipid lowering medications  
  Yes 4160 21.2 815 26 850 22.5 1050 18 1445 20 <0.001 0.64
  No 2086 21.8 978 22.9 567 22.9 329 17.3 212 20.3 0.09
# Discharge medications (beta blockers, calcium channel blockers, long-acting nitrates, ACE-inhibitors) 
  0-1 2735 18.2 819 18.8 689 18.1 565 16.3 662 19.3 0.96 0.001
  ≥ 2 3508 23.8 974 29 727 27 812 18.8 995 20.5 <0.001 
*P value for test of trend in angina rates within each characteristic; ** P value for interaction term of characteristic with wave 
 
 Table 2.4: Predictors of one year post-PCI angina in contemporary practice 
 
Baseline factors 
only 
In-hospital 
factors and 1-yr 
outcomes added 
 
Relative risk 
(95% CI) 
P value 
 
Relative risk 
95% CI 
P value 
 
Female (vs Male) 1.28 (1.06-1.55) 0.01 1.24 (1.04 - 1.48) 0.02 
Whites (vs non-whites) 0.99 (0.79 - 1.25) 0.95 0.99 (0.80 - 1.23) 0.93 
Age ≥ 65 years (vs < 65 yrs) 0.73 (0.60 - 0.89) <0.01 0.77 (0.65 - 0.93) 0.01 
History of congestive heart failure 1.27 (0.95 - 1.70) 0.1 1.25 (0.94 - 1.65) 0.12 
Concomitant peripheral vascular 
disease 
1.35 (1.02 - 1.80) 0.04 1.21 (0.92 - 1.59) 0.16 
Prior bypass surgery 1.45 (1.17 - 1.78) 0.001 1.38 (1.13 - 1.69) <0.01 
Prior PCI 1.28 (1.05 - 1.54) 0.02 1.19 (1.00 - 1.43) 0.05 
Index PCI for acute MI (vs stable 
or unstable angina) 
0.71 (0.56 - 0.89) <0.01 0.75 (0.61 - 0.92) 0.01 
Discharged on antiplatelets - - 0.74 (0.49 - 1.02) 0.06 
MI during 1-year follow-up - - 1.54 (1.13 - 2.12) 0.01 
Repeat PCI during one-year 
follow-up 
- - 1.52 (1.21 - 1.90) <0.001 
Additional covariates considered but did not enter model: Baseline factors: concomitant 
cerebrovascular disease, history of hypercholesterolemia, significant graft body disease before 
index procedure, presence of native total occlusions; In-hospital and one year outcomes: use of  
 59
 Table 2.4 continued 
Gp IIb/IIIa inhibitors < 24 hours or during index procedure, Use of drug-eluting stents, overall use 
of balloons, discharge medications: long-acting nitrates, beta blockers, angiotensin-converting 
enzyme inhibitors and calcium channel blockers.  
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Figure 2.1: Prevalence of one-year post-procedural angina by primary reason for index PCI in the 
NHLBI-sponsored 1997-2004 Dynamic Registry 
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Figure 2.2: Relative risk of one year post-PCI angina in the overall cohort and in 
specific subsets in the NHLBI-sponsored 1997-2004 Dynamic Registry 
Covariates in the final model for the overall cohort: Age ≥ 65 years, female gender, race, prior 
PCI, prior CABG, severe concomitant non-cardiac disease, history of hypertension, smoking 
status, primary reason for index PCI (stable or unstable angina, acute MI, other reasons), overall 
stent use, repeat PCI over one year, discharged on ≥2 of the following medications (beta-
blockers, calcium-channel blockers, ACE-inhibitors, long-acting nitrates) 
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 3.1 ABSTRACT 
Durability of symptom-relief, following percutaneous coronary intervention (PCI), has often 
been attributed to repeat revascularization. However, technological evolution in the field has 
resulted in dramatic reductions in rates of restenosis and repeat intervention. Our objective, 
therefore, is to document temporal trends in post-PCI supplemental therapy and evaluate its 
influence on quality of life (QOL), in 6246 consecutive patients in the NHLBI-sponsored 1997-
2004 Dynamic registry. In the overall cohort, more patients reported use of pharmacological 
maintenance therapy (PMT, ≥1 of beta-blockers, calcium channel blockers and long-acting 
nitrates) both within and across the four waves (wave 1: 62%, wave 2: 64%, wave 3: 67%, wave 
4: 72%, Ptrend <0.001), with fewer repeat interventions. In every wave, more symptom-free 
patients, compared to symptomatic counterparts, reported use of no additional therapy (wave 1: 
19 vs 11 %, wave 2: 20 vs 12%, wave 3: 19 vs 14 %, wave 4: 17 vs 15 %, P < 0.05 for all). QOL 
scores were higher with better physical activity and health status ratings in asymptomatic 
patients. On average, adjusted QOL scores improved significantly over time (mean scores – 6.2, 
6.5, 6.6 and 6.6 for waves 1,2,3,4; Ptrend: 0.01), but more importantly, differed by aggressiveness 
of therapy (mean scores – none: 6.6, MT: 6.5, repeat PCI: 6.0 and bypass surgery ± PCI: 6.3; 
Ptrend: 0.03). Use of PMT, following initial PCI, has increased over time, with concomitant 
reduction in repeat interventions. Patient-reported QOL is influenced by nature of supplemental 
therapy and warrants consideration in post-PCI management.  
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 3.2 BACKGROUND 
Durability of symptom-relief with percutaneous coronary intervention (PCI), either alone or 
when compared to bypass surgery, is often attributed to subsequent repeat interventions and 
reliance on anti-anginal medications 26, 62. Restenosis, necessitating repeat PCI, has also been 
shown to negatively impact patient’s quality of life (QOL) following index procedure 63. In the 
last few decades, however, the field of PCI has witnessed an explosion of new devices and 
improved adjunct therapy. Consequently, contemporary procedures, performed in heterogeneous 
population, are safer but more importantly, have resulted in a drastic reduction in restenosis and 
repeat interventions 24,27,43. Additionally, in Paper 2 of this dissertation, favorable temporal 
trends were seen in patient-perceived symptoms, following initial PCI. Nevertheless, the related 
impact on the ‘price’ for achieving symptom-free status and its bearing on QOL remains to be 
explored.   
The objectives of this analysis, therefore, are to 1) document temporal trends in 
aggressiveness of post-procedural therapy over one year, within anginal status, and 2) evaluate 
its influence on QOL indicators, in consecutive patients undergoing PCI in the NHLBI-
sponsored 1997-2004 Dynamic registry.  
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 3.3 METHODS  
3.3.1 The NHLBI-sponsored 1997-2004 Dynamic Registry 
Consecutive patients undergoing PCI were sequentially enrolled in recruitment waves: Wave 1: 
1997-98, Wave 2: 1999, Wave 3: 2001-2002, and Wave 4: 2004; each cohort was enriched 
(oversampled) with women and minorities 24,44. Baseline information on patient and procedural 
characteristics were ascertained by research coordinators trained in data collection. Written 
informed consent was obtained from participants at baseline for enrollment and follow-up 
contacts. The study protocol was approved by the Institutional Review Board of the University 
of Pittsburgh and those of all sites involved. 
Patients were contacted by telephone, mail or during clinic visits, at one year of follow-
up and information on angina and medication use, in past 6 weeks, physical activity (sedentary, 
mild, moderate, or strenuous), health status (poor, fair, good, very good and excellent), and QOL 
(11-point scale anchored between zero (dead or worse than being dead) and 10 (best)) were 
obtained. Hospitalizations for angina, myocardial infarction (MI), bypass surgery (CABG), and 
repeat PCI over one year were also recorded. Repeat PCI data included any procedure performed 
during a subsequent hospitalization after the index procedure. CABG included both in-hospital 
and post procedure events. Aggressiveness of supplemental therapy, following index PCI, was 
classified as follows: none (or only sublingual nitroglycerin as needed), pharmacological 
maintenance therapy (PMT, ≥1 of beta-blockers, calcium channel blockers and long-acting 
nitrates), repeat PCI, and CABG +/- repeat PCI.   
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 Of the 8788 patients enrolled in the registry, ~ 90% consented for follow-up. At one year, 
6246 consecutive patients provided angina information and constitute the analysis sample in this 
report.  
3.3.2 Statistical analyses 
Prevalence of symptom-free status, physical activity and health status at follow-up and 
aggressiveness of therapy are summarized as percentages and quality of life scores are 
summarized as mean (SD). Temporal trend in aggressiveness of therapy across the waves was 
assessed using the Jonckeheere-Terpsta test. Patient-reported outcomes of physical activity, 
health status and QOL scores were compared over time, by anginal status and in each level of 
aggressiveness of therapy. Difference in physical activity and health status (dichotomized as 
Poor / Fair vs Good/Very Good/Excellent) by anginal status was compared using the Cochran-
Armitage or Chi-square tests, as appropriate. Difference in QOL scores by anginal status, in each 
wave, and trends over time was assessed using linear regression (PROC GLM in SAS); adjusted 
mean scores across waves were obtained from multivariate models that included age, gender, 
race and concomitant comorbidities (history of diabetes, hypercholesterolemia, hypertension, 
congestive heart failure, severe non-cardiovascular diseases). All analyses were performed with 
SAS version 9.1 (SAS Institute Inc, NC). 
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 3.4 RESULTS 
Of the 6246 patient alive and providing angina formation at one year, ~80% reported being 
angina-free (wave 1: 76%, wave 2: 77%, wave 3: 82%, wave 4:80%; Ptrend: <0.001). Significant 
temporal trends were observed in the need and type of additional therapy, both in the overall 
cohort (Ptrend: <0.001) as well as by anginal status (Ptrend in those with angina: 0.02, Ptrend for 
angina-free patients: 0.001) (Table 3.1). PMT was the predominant type of additional therapy 
both within and across the four waves (wave 1: 62%, wave 2: 64%, wave 3: 67%, wave 4: 72%). 
Comparison between angina-free and symptomatic patients revealed important differences. In 
every wave, more symptom-free patients reported no additional therapy, compared to 
symptomatic counterparts (wave 1: 19 vs 11 %, wave 2: 20 vs 12%, wave 3: 19 vs 14 %, wave 4: 
17 vs 15 %). However, when supplementary treatment was required, angina-free status was 
achieved more often with maintenance therapy and fewer repeat interventions (more CABG and 
fewer repeat PCI in asymptomatic patients, compared to symptomatic counterparts). Trends in 
individual drug classes, used as maintenance therapy, showed that while fewer patients initially 
discharged on calcium channel blockers and long-acting nitrates, reported use at follow-up, use 
of beta-blockers increased across the waves (Table 3.2).  
3.4.1 Quality of life following index PCI  
Of the 5987 consecutive patients with QOL scores, mean QOL was significantly better in 
angina-free patients when compared to those reporting symptoms (mean(SD) score:7.3(1.9) vs 
5.9 (2.1), P<0.001) at 1 year; among those with angina, QOL decreased as severity increased 
(mean (SD) score by CHC class: I: 6.4(1.9), II: 6.1(2), III:5.4(2.2), IV: 5.6(2.1), Ptrend: <0.001).  
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 Profile of follow-up physical activity, in each wave, was better in angina-free patients than their 
symptomatic counterparts (sedentary: 8 vs 15%, mild: 38 vs 48%, moderate: 46 vs 33%, 
strenuous: 8 vs 4%, Ptrend: <0.001). 
Over time, mean QOL scores significant improved in the overall cohort and in both 
symptom strata (mean (SD) scores – Angina: wave 1: 5.8 (2), wave 2: 5.8(2), wave 3: 5.9(2), 
wave 4: 6.2(2), Ptrend: 0.01; No Angina: wave 1: 7.1 (2), wave 2: 7.4(2), wave 3: 7.4(1.9), wave 
4: 7.3(1.9), Ptrend: 0.01). Adjustment for potential confounders did not alter the pattern in the 
overall cohort (Table 3.3). 
3.4.2 QOL and aggressiveness of supplemental therapy following index PCI 
In general, patient-reported QOL indicators (QOL scores, physical activity, health status) varied 
by aggressiveness of additional therapy (Table 3.3). When analyzed within therapy subsets, 
mean QOL scores (unadjusted and adjusted) increased over time, albeit with varying statistical 
significance (Table 3.4). However, more patients in the ‘no therapy’ subset, in the recent waves, 
reported poor health status (wave 1: 4 %, wave 2: 5%, wave 3: 6% wave 4: 8%, Ptrend: 0.02). 
Exploratory analysis in the small subset (N= 167) of symptomatic patients with no additional 
therapy showed trend towards increasing age with significantly more concomitant non-cardiac 
disease and history of prior revascularizations over time. Although procedural success did not 
differ across the waves, fewer lesions were attempted in setting of greater baseline disease 
burden (Table 3.5).  
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 3.5 DISCUSSION 
The NHLBI-sponsored Dynamic registry was primarily initiated to provide a snapshot of PCI 
with focus on patient and lesion profile, improvements in technology and the associated impact 
on clinical outcomes. Our report extends this to document temporal trends in supplementary 
therapy, following index PCI and its effect on patient-reported quality of life at one year.   
Since its initial use in 1977 8, PCI has seen rapid advancements resulting in high success 
rates, improved safety and reduced need for repeat interventions 18,43. Previous studies have also 
reported favorable impact on post-procedural symptoms 31,45,49, albeit the lack of demonstrable 
mortality benefit.  Few, however, explored the need and nature of post-procedural treatment in 
achieving symptom-free status or the associated impact on patient’s quality of life. In the pre-
stent era, ~ 1 in four patients, who underwent PCI outside of acute MI setting and were angina-
free at one year, required repeat intervention (6% CABG and 19% repeat PCI) 4. Subsequent 
analysis of symptomatic patients in the NHLBI-sponsored Dynamic registry showed lower rates 
repeat revascularization with increased use of maintenance therapy at one year 45. This trend, as 
observed in our report, has continued over time - not only is symptom-free status achieved more 
often with pharmacological management, but more so in the setting of fewer repeat 
interventions. Coronary revascularization is an ideal opportunity for implementing evidence-
based guidelines of post-procedural management and to this end, favorable temporal trends have 
been demonstrated in Paper 2 of this dissertation. Additionally, as seen in this report, more 
patients, when discharged on these medications, report use in the recent waves, suggestive of 
improved compliance. Early studies of PCI have often viewed reliance on anti-anginal therapy as 
a disadvantage of the procedure and admittedly, baseline use or reasons for discharge 
prescription were not collected in our registry. Nevertheless, improved understanding of 
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 atherosclerosis, over the past few decades, has allowed for more effective use of cardiac 
medications, including beta blockers, in preventing recurrent events 64, 65, 66, 67. Given the reduced 
need for long-acting nitrates over time, we speculate that beta blocker use, along with those of 
other recommended medications, probably reflects effective secondary prevention.  
Patient’s perspective of effectiveness of a treatment modality largely differs from clinical 
success. Patient-centered outcomes, including symptoms and quality of life, therefore, are 
gaining attention, both as part of decision-making as well as assessment of procedural 
performance 68,69. Coronary artery disease, per se, imposes a considerable burden of illness and 
baseline symptoms significantly affect quality of life, even after percutaneous treatment 70. Serial 
measurements of post-procedural health status (anginal frequency, QOL scores and physical 
function) showed that the greater improvement following CABG, compared to PCI, was 
primarily driven by restenosis in the latter group 63. Our report extends this to show varying 
influence of specific type of additional therapy on QOL indicators, even in the absence of 
symptoms. Although treatment-specific QOL scores improved over time, there was considerable 
variation by aggressiveness of therapy. Clearly, this speaks to the multi-dimensional nature of 
QOL, which is not solely determined by symptoms, and therefore, must be considered during 
long-term evaluation.  
The trend seen in poor health status when not on any additional therapy was mainly 
driven by symptomatic patients. Though small in number, the profile of symptomatic patients 
reflected an aging cohort, with prior revascularization and concomitant comorbidities, who may 
no longer be suitable for repeat interventions. On the other hand, lack of continued access to 
health-care facilities, especially among those with symptoms, cannot be ruled out. In a study of 
480 patients, undergoing revascularization, affordability of health care was directly associated 
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 with post-procedural recovery, especially among PCI patients 71. Then again, health status in this 
report was assessed at a single time point and extended follow-up may have captured additional 
therapy.  
The QOL benefits of PCI, alone or in comparison to other treatment modalities, are seen 
to vary in its various dimensions when captured using generic and disease-specific 
questionnaires 72,73,74,75. The choice of instrument, however, is largely influenced by availability 
of resources, more so in registries that rely on voluntary participation. Information on patient-
reported outcomes in our registry, though not extensive, was captured using brief questions from 
validated instruments 76, well-suited for telephone-based interviews. Further proof of validity, in 
this cohort, comes from the inverse relationship seen with worsening symptoms. Indeed, even 
with this limited information, our report demonstrates overall improvement in patient-reported 
indicators following PCI. In addition to being subjective with the potential recall bias, QOL is 
also influenced by social environment, relationships, personal values and emotions, details not 
collected in our registry. Furthermore, lack of baseline and serial measurements limits our ability 
to document magnitude and durability of improvement, both within individuals as well as 
between waves. 
3.6 CONCLUSION 
Angina-free status in one-year survivors of PCI is increasingly achieved with pharmacological 
therapy with fewer repeat revascularizations. Patient-reported quality of life is influenced by 
aggressiveness of therapy, following initial procedure and warrants consideration in post-
procedural management. 
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 Table 3.1: Temporal trends in supplemental therapy, following index PCI, in the NHLBI-
sponsored 1997-2004 Dynamic Registry 
  Dynamic Registry 
  Wave 1 Wave 2 Wave 3 Wave 4 
Ptrend
Entire cohort (N,%) (N=1793) (N=1417) (N=1379) (N=1657)  
None                           (1090,17.5) 17.3 18.3 17.8 16.7 <0.001 
PMT*                         (4126,66.1) 61.6 64.3 66.9 71.7  
Repeat PCI                  (722,11.6) 14.2 11.2 11.3 9.2  
CABG +/- Repeat PCI  (308,4.9) 6.9 6.2 4 2.5  
Patients with angina (N=436) (N=321) (N=246) (N=332)  
None 10.8 11.5 14.2 14.5 0.02 
PMT* 64.2 64.8 65 65.7  
Repeat PCI 19.7 18.4 16.7 18.1  
CABG +/- Repeat PCI 5.3 5.3 4.1 1.8  
Patients with no angina (N=1357) (N=1096) (N=1133) (N=1325)  
None 19.4 20.3 18.5 17.2 0.001 
PMT* 60.7 64.1 67.3 73.2  
Repeat PCI 12.5 9.1 10.2 6.9  
CABG +/- Repeat PCI 7.4 6.5 4 2.6  
Difference between anginal 
status (p value) 0.01 0.001 0.02 0.001  
* PMT: Pharmacological maintenance therapy (≥1 of beta-blockers, calcium channel blockers and long-
acting nitrates) 
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 Table 3.2: One year use of evidence based-medications among those prescribed at 
discharge in the NHLBI-sponsored 1997-2004 Dynamic Registry 
 % use at follow-up 
 Wave 1 Wave 2 Wave 3 Wave 4 Ptrend
Aspirin  86.8 87.6 86.6 90.9 0.001 
Lipid lowering medications  80.1 83.5 84.7 86.8 <0.001 
Antiplatelets** 2.0 4.5 17.1 60.6 <0.001 
ACE-Inhibitors  65.4 67.5 69.9 70.8 0.03 
Beta blockers 78.8 81.1 81.8 84.6 <0.001 
Long-acting nitrates 54.9 43.5 44.4 48.8 0.02 
Calcium channel blockers  61.4 64.5 60.7 59.6 0.58 
** Information on follow-up use of clopidogrel not routinely collected in waves 2 and 3 
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 Table 3.3: One-year quality of life indicators by aggressiveness of therapy in the NHLBI-
sponsored 1997-2004 Dynamic Registry 
 
None 
(N=1031)
PMT 
(N=3983)
Repeat PCI
(N=677) 
CABG +/- PCI 
(N=296) 
Ptrend
QOL ratings (mean)      
    Unadjusted 7.2 7 6.6 6.9 0.05 
    Adjusted*  6.6 6.5 6.0 6.3 0.03 
Health status (%)     <0.001
    Poor / Fair 25 28 35 29  
    Good/Very Good/Excellent 75 72 65 71  
Physical Activity     <0.001
    Sedentary 11 9 11 10  
    Mild 34 41 44 39  
    Moderate 45 43 40 43  
    Strenuous 11 7 6 9  
*Adjusted for age, gender, race, and concomitant comorbidities (history of diabetes,
hypercholesterolemia, hypertension, congestive heart failure, severe non-cardiovascular 
diseases) 
 
 
 
 
 
 
 
 75
 Table 3.4: Temporal trends in quality of life and health status by aggressiveness of therapy 
in the NHLBI-sponsored 1997-2004 Dynamic Registry 
 Wave 1 Wave 2 Wave 3 Wave 4 Ptrend*
Overall 
QOL ratings      
Unadjusted 6.8 7 7.1 7.1 <0.001 
Adjusted † 6.2 6.5 6.6 6.6 <0.001 
% Poor / Fair health status 27 31 27 29 0.35 
Aggressiveness of additional therapy 
None +/- Sublingual NTG       
QOL ratings      
Unadjusted 7.1 7.5 7.2 7 0.33 
Adjusted† 6.4 6.9 6.7 6.4 0.65 
% Poor / Fair health status, Overall 20 23 24 34 <0.001 
      Patients with angina 36 46 46 54 0.09 
      Patients with no angina 17 19 20 30 0.001 
PMT‡       
QOL ratings      
Unadjusted 6.8 7.0 7.2 7.2 <0.001 
Adjusted† 6.2 6.4 6.6 6.6 <0.001 
% Poor / Fair health status, Overall 27 32 27 27 0.56 
      Patients with angina 48 56 49 49 0.96 
      Patients with no angina 20 24 22 22 0.46 
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 Table 3.4 continued      
Repeat PCI       
QOL ratings      
Unadjusted 6.3 6.4 6.7 6.9 0.01 
Adjusted† 5.8 5.9 6.2 6.4 0.01 
% Poor / Fair health status, Overall 33 38 33 38 0.38 
      Patients with angina 55 61 44 52 0.43 
      Patients with no angina 21 25 30 29 0.08 
CABG +/- Repeat PCI       
QOL ratings      
Unadjusted 6.9 6.8 6.7 7.2 0.47 
Adjusted† 6.4 6.3 6.3 6.7 0.45 
% Poor / Fair health status, Overall 31 28 29 24 0.42 
      Patients with angina 57 41 50 33 0.35 
      Patients with no angina 26 25 24 23 0.73 
* Test for trend: QOL scores – Linear contrast in general linear models, Health status – 
Cochran-Armitage test; †Adjusted for age, gender, race, and concomitant comorbidities 
(history of diabetes, hypercholesterolemia, hypertension, congestive heart failure, severe 
non-cardiovascular diseases) ‡ PMT: Pharmacological maintenance therapy (≥1 of beta-
blockers, calcium channel blockers and long-acting nitrates) 
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 Table 3.5: Profile of symptomatic patients with no additional therapy over one year in the 
NHLBI-sponsored 1997-2004 Dynamic Registry 
 Dynamic Registry waves 
1 2 3 4 
 (N=47) (N=37) (N=35) (N=48) Ptrend
Age > 65 years 34 37.8 54.3 45.8 0.13 
Female 29.8 21.6 40 25 0.98 
White 89.4 94.6 80 85.4 0.28 
Mean ejection fraction 55.2 49.5 52.7 52.4 0.67 
Prior CABG 10.6 16.2 20 18.8 0.25 
Prior PCI 27.7 24.3 42.9 41.7 0.06 
Prior MI 36.2 27.8 14.7 25.5 0.15 
Severe concomitant non-cardiac disease 31.9 18.9 54.3 47.9 0.02 
  Cerebrovascular 6.4 2.7 8.6 8.3  
  Peripheral artery disease 4.3 0 2.9 16.7  
  Pulmonary Disease 12.8 2.7 11.4 20.8  
  Cancer 4.3 2.7 17.1 4.2  
  Renal Failure/Insufficiency 0 2.7 0 8.3  
  Other 6.4 8.1 25.7 12.5  
History of Diabetes 21.7 27 28.6 25 0.70 
History of Congestive heart failure 8.7 5.4 20 10.9 0.38 
History of Hypertension 60 59.5 68.6 75 0.09 
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 Table 3.5 continued      
Primary Reason for index PCI     0.56 
  Asymptomatic / Other 4.3 5.4 11.4 6.3  
  Stable Angina 27.7 24.3 11.4 39.6  
  Unstable Angina 46.8 40.5 62.9 29.2  
  Acute MI 21.3 29.7 14.3 25  
Baseline disease status     0.01 
  Single vessel 63.8 62.2 34.3 41.7  
  Double vessel 23.4 13.5 37.1 35.4  
  Triple vessel 10.6 24.3 28.6 22.9  
Circumstances of Procedure     0.27 
  Elective 63.8 40.5 40 52.1  
  Urgent 25.5 48.6 51.4 33.3  
  Emergent 10.6 10.8 8.6 14.6  
≥2 Lesions attempted 25.5 29.7 17.1 20.8 0.38 
Number of Vessels Attempted     0.04 
    1 native vessel only 93.6 91.9 82.9 81.3  
    2 -3 native vessels only 4.3 0 5.7 10.4  
    Graft +/- native vessels (s) 2.1 8.1 11.4 8.3  
Complex lesions attempted 66 70.3 54.3 43.8 0.01 
Device Use     0.57 
  Balloon only or with drug 12.8 13.5 5.7 4.2  
  Balloon & stent/stent only 61.7 64.9 77.1 75  
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 Table 3.5 continued      
  Balloon & stent & RA 10.6 10.8 2.9 2.1  
  RA only/balloon & RA 12.8 5.4 0 0  
  Other device 2.1 2.7 14.3 16.7  
In-hospital outcomes      
Procedural complications 19.1 10.8 2.9 4.2 0.01 
Angiographic Success (partial or total) 97.9 94.6 100 97.9 0.34 
Procedural Success 97.9 91.9 100 97.9 0.56 
Anti-anginal medications at discharge       
Beta blockers 44.7 59.5 51.4 54.2 0.49 
Long acting nitrates 31.9 13.5 14.3 12.5 0.02 
Calcium channel blockers 27.7 10.8 14.3 8.3 0.02 
Medications at follow-up      
Aspirin   76.6 64.9 77.1 85.4 0.18 
ACE inhibitors 34 35.1 40 54.2 0.40 
Angiotensin receptor blockers 0 2.7 14.3 16.7 0.001 
Vasodilators / other anti-hypertensive 
medications 8.5 8.1 2.9 10.4 0.91 
Diuretics 14.9 21.6 11.4 16.7 0.92 
Digitalis 6.4 8.1 0 2.1 0.14 
Lipid lowering medications 38.3 59.5 82.9 89.6 0.002 
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 GENERAL DISCUSSION 
SUMMARY OF FINDINGS 
This dissertation, designed as three research papers, was primarily aimed at capturing the 
evolution of PCI and the associated impact on clinical and patient-reported outcomes, in 
prospective multicenter registries of real world clinical practice. 
In Paper 1 , temporal trends in patient, lesion, and procedural characteristics were 
evaluated and in-hospital and one year outcomes were compared between the NHLBI-sponsored 
1985-86 PTCA registry (era of balloon angioplasty) and 1997-2004 Dynamic registry  (era of 
stents, brachytherapy and drug-eluting stents) cohorts. Results of this analysis revealed the 
heterogeneity in patients (and lesions) undergoing PCI, since its initial use 8, as well as the 
selective revascularization strategy in setting of greater baseline disease burden.  Between 1985-
86 and 2004, a wide variety of devices – balloons, bare metal stents, brachytherapy and more 
recently, drug-eluting stents – have been used. Use of dual antiplatelet therapy (aspirin and 
ticlopidine /clopidogrel) and other medications with evidence-based rationale have increased 
over time. Clinical performance, as characterized by procedural success and complications, 
dramatically improved with improved effectiveness (reduced need for repeat procedures) at one 
year. Even so, very little impact was observed in post-procedural mortality. 
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 In Paper 2, prevalence of one-year angina was evaluated across the four waves of the 
Dynamic registry, representing the advent (wave 1) and uniform use (wave 2) of bare metal 
stents, intra-coronary radiation (wave 3) and advent of drug-eluting stents (wave 4); significant 
predictors in contemporary practice were identified. This analysis, from a large prospective, 
multicenter registry, documented favorable temporal trends with reduced prevalence and risk of 
post-PCI angina in a decade of real world clinical practice.  Use of evidence-based secondary 
pharmacological therapy also improved over time. Differential impact of PCI era on post-
procedural angina was observed in patients with these specific characteristics – diabetes, prior 
MI and prior revascularization. In contemporary practice, even with the improved secondary 
management, women and patients with prior or repeat PCI remain at high-risk for post-
procedural symptoms. 
In Paper 3, temporal trends in supplemental therapy following index procedure, 
specifically to achieve symptom-free status, were explored and the associated impact on quality 
of life indicators evaluated. In keeping with the evolution seen in the field, there was an observed 
shift towards greater use of maintenance therapy (more beta blocker use with fewer reports of 
nitrate and calcium channel blocker use) with concomitant reduction in rates of CABG and 
repeat PCI, in angina-free patients. Although patient-reported quality of life, significantly 
different by symptom status, improved over time, it was seen to vary by need and aggressiveness 
of supplemental therapy.  
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 PERCUTANEOUS CORONARY INTERVENTION – THEN AND NOW 
The above findings, from multicenter registries spanning two decades, together with those from 
previous reports 77, 27, 22, 78, speak to the dynamic nature of PCI. This transformation is indeed 
dramatic for a field initially considered in either single discrete lesions that did not warrant 
invasive surgeries or in sick patients in whom surgery was contraindicated or had to be deferred.  
Clinical outcomes 
For a long period of time, percutaneous treatment with balloon angioplasty and then bare-metal 
stents was plagued with abrupt vessel closures and restenosis, necessitating repeat procedures. 
This then became the driving force for the majority of innovations and improvisations in the 
field. It is, therefore, encouraging to see the dramatic reduction in procedural complications and 
rates of late repeat procedures, be it PCI or CABG, following the index procedure. On the other 
hand, the observed increase in early repeat PCI rates, which were small to begin with, are 
probably representative of a shift in preference for this technique, as opposed to early triage to 
CABG seen in initial cohorts. 
In the last thirty years, the field has indeed come a long way with high procedural success 
and improved effectiveness (reduced repeat procedures). However, although rates of myocardial 
infarction (in-hospital and one year) have reduced over time, lack of demonstrable overall 
mortality benefit is intriguing. Detailed exploration of trends in outcomes by specific 
characteristics was beyond the scope of this dissertation. Nevertheless, previous publications 
from these registries have identified some subsets that may be responsible for this trend. 
Comparison of one year outcomes between patients undergoing PCI for stable versus unstable 
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 angina showed little change in mortality rates in the latter cohort over the past 16 years 79. In 
another report of 2,839 patients with complex lesions (defined as a lesion showing evidence of 
thrombus, calcification, bifurcation or ostial location, or chronic occlusion),  both in-hospital and 
one year mortality rates were higher, compared to attempts on simple lesions 30.  
Patient-reported outcomes 
The focus of Papers 2 and 3 was temporal trends and impact of the aggressiveness of medical 
therapy on patient-reported outcomes among one-year survivors of PCI. Post-procedural 
symptoms and quality of life (QOL) indicators, evaluated during follow-up, were secondary 
outcomes of interest in the NHLBI-sponsored registries that relied on voluntary participation of 
clinical sites.  As a result, brief questions, reliable and well suited for telephone based interviews, 
as opposed to extensive multidimensional questionnaires, were used for data collection. To the 
best of our knowledge, this is the first report to document favorable temporal trends in these 
outcomes and also, delineate the varying impact of aggressiveness of supplemental therapy in 
real world practice. 
Analysis of patient-perceived outcomes is fitting given that, outside of acute settings, 
relief of symptoms to improve QOL is the underlying goal of revascularization. To this end, it is 
encouraging to see that the overall prevalence and risk of one-year angina has decreased over 
time, paralleling technological evolution and improved use of secondary pharmacotherapy in the 
field. Interestingly, specific characteristics were seen have a differential impact on 1-year angina. 
Presence of diabetes was associated with marked reduction in post-PCI angina over time, thus 
mirroring favorable trends in other in-hospital and one year outcomes in this subset 51. Patients 
with prior PCI, on the other hand, were seen to have an increased risk, warranting closer 
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 attention.  Follow-up angina, of any prevalence, is concerning, more so, when observed in an era 
of improved procedural performance and aggressive secondary management. Given that the 
reported predictors were identified in symptomatic patients (reason for index PCI is stable or 
unstable angina or acute MI), these characteristics could well be representative of high ischemic 
burden. On the other hand, although recruitment in Wave 4 coincided with the early phase of 
first-generation DES use, off-label use cannot be ruled out. The overall increased (statistically 
non-significant) risk seen with DES use could, therefore, be associated fallout. The ongoing 
debate regarding inappropriate use of PCI in chronic stable angina, that could be medically 
managed, highlights another possible issue 80. 
 Comparability of benefits between revascularization techniques has often been attributed 
to additional procedures and reliance on anti-anginal medications in the PCI arm. This analysis, 
consistent with other studies, has demonstrated a reduction in need for repeat interventions 
following PCI. Furthermore, temporal trends in one-year asymptomatic status have been 
favorable with concomitant reduction in prescription and use of long-acting nitrates. With this as 
the background, Paper 3 was aimed at revisiting the need and aggressiveness of additional 
therapy following index PCI. Indeed, not only is asymptomatic status achieved more often today, 
but it is also achieved with more pharmacological therapy while fewer repeat interventions. 
Ideally, post-procedural management takes into consideration symptoms and functional 
limitations, in addition to objective evidence of ischemia.  However, patient-centered outcomes 
have for long been considered too soft an endpoint to be incorporated in clinical practice. 
Patient’s perspective of disease burden also differs considerably from that of the clinician 81, 82. 
With the recent goals set forth by the Institute of Medicine 68, this is expected to change. The 
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 present finding that patient-reported QOL scores are influenced by the type of additional 
intervention further underscores the importance of incorporating these measures.  
ROLE OF REGISTRIES IN CONTEMPORARY PRACTICE 
Healthcare practice and clinical guidelines have relied on randomized clinical trials (RCT) for 
evidence regarding treatment strategies. However, registries, in spite of some inherent biases, 
have held a prominent place in evaluation of real world clinical practice 83,24, 27,84,42.   
 Registries have been credited with highlighting widespread use of angioplasty 85 and 
subsequently prompting trials that compared it to other treatment options 86, 87. More recently, 
DES-related thrombosis 42 was first identified using registry data, with no prior evidence in early 
trials 12,13. Furthermore, characteristics identified as predictors (premature antiplatelet 
discontinuation, comorbidities like renal failure, diabetes, and low ejection fraction) are not often 
encountered in the controlled conditions of RCTs. This is because trials are designed to answer 
specific questions and the participants are carefully chosen, with inclusion / exclusion criteria, to 
ensure homogeneity between the different arms to optimize responsiveness. Registries, in 
contrast, are population-based with an aim to mirror ‘real world’ practice. Therefore, while RCTs 
are designed for proving efficacy of treatments, registries help with the timely evaluation of 
safety and effectiveness. With emerging concerns of mortality and stent thrombosis risk with 
DES use, and the Food and Drug Administration mandating extended postmarket surveillance, 
the role of registries in clinical research, though often underappreciated, is gaining prominence.  
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 PUBLIC HEALTH SIGNIFICANCE 
The burden of CAD is quite immense with an estimated 950,000 deaths each year and an 
approximate $368.4 billion in associated heath care costs 1. PCI, as a treatment modality, has 
gained rapid acceptance resulting in a 300% increase in the number of procedures in the past two 
decades. Specifically, stent implantation has doubled 88 and 90% of these stents in the U.S are 
DES 89. Any treatment modality, when applied in this magnitude, warrants frequent and timely 
monitoring of effectiveness and safety, a case in point being the latest controversy with DES use.  
 In the last few decades, there has also been much improvement in our understanding of 
atherosclerotic process. As a result, the observed decline in cardiovascular death rates since 1968 
90 has been attributed to a number of factors including effective primary preventive measures and 
better treatment options. Developments in revascularization techniques, especially PCI, have 
influenced its feasibility in cases that would otherwise have been medically/surgically treated. 
However, the U.S. population is rapidly ageing, resulting in a cohort of survivors at high risk for 
cardiac comorbidities and subsequent complications, necessitating revascularizations. 
Paradoxically, the co-existing comorbidities will adversely affect the outcomes.  
 This dissertation provides the much-needed time-sensitive documentation of changing 
clinical practice and associated impact on patients, in the real world.  The NHLBI-sponsored 
1985-86 PTCA and 1997-2004 Dynamic registries were specifically initiated for this purpose 
and taken together, are one of the few available sources of systematic and comprehensive data to 
this end. The findings are especially fitting at this juncture wherein the field of PCI appears to be 
at crossroads - restenosis, the long-time Achilles heel, may have been overcome, but there are 
emerging concerns of late stent thrombosis and long-term safety.  
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 FUTURE RESEARCH 
We now have a snapshot of PCI in the last two decades of clinical practice and its impact on one-
year outcomes from two perspectives – the provider (physician) and the receiver (the patient). 
However, with plateauing of success rates and single-digit restenosis rates becoming a reality 12, 
it just may be the time to pay closer attention to long-term safety, revisit appropriateness of use 
and evaluate cost-effectiveness of the procedure.  
PCI is probably one of the few fields in clinical medicine, which utilizes new technology 
with rapid fervor. However, in spite of the overall favorable trends, extensive research is still 
needed to understand the optimal choice of revascularization procedures in complex anatomy 
(chronic total occlusions, small caliber vessels, diffuse disease, and bifurcations). A recent report 
comparing occluded an non-occluded lesions, in the Dynamic registry, showed a decrease in 
attempts of occluded lesions, with little change in associated success rates 44. Bifurcation 
stenting, even with DES, has met with high restenosis rates 91 and is an independent predictor of 
adverse events in distal left main stenosis. 
Approval of stents and other devices follows rigorous evaluation in randomized trials 
carried out in select, homogenous patient and lesion populations. However, patient profiles in the 
real world are quite heterogeneous and ~50% of DES implantation occurs in off-label and 
untested circumstances 16.  The associated concerns of late stent thrombosis 92, 14 and the 
potential high risk of long-term mortality and Q-wave MI 15 have sparked widespread debate. 
The role of dual antiplatelet therapy and the uncertainty regarding appropriate duration have also 
come to the forefront. More recently, one year results from the Clinical Outcomes Utilizing 
Revascularization and Aggressive DruG Evaluation (COURAGE) trial were made available 93. 
This trial, designed to compare PCI + optimal medical therapy with medical therapy alone as 
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 initial management strategy, included 2287 patients with stable CAD followed over 2.5 to 7 
years. No significant difference was seen in the primary composite endpoint of death and 
nonfatal MI with initial strategy of PCI when compared to medical therapy alone. Additionally, 
although relief of angina was achieved to a greater degree with PCI, substantial improvement 
was also seen in the medical arm. These results highlight the notable progress in the field of 
pharmacological therapy, but more importantly, rekindle questions regarding appropriate use of 
PCI.  
Medical decision-making is a complex, multifactorial process with interplay of physician 
discretion, patient preference and treatment affordability. Durability of treatment benefits relies 
in effective and continued post-procedural management, including implementation of 
recommended guidelines for risk factor modification. Patients undergoing PCI are documented 
cases of CAD and therefore, it is only intuitive that these measures would be effectively stepped 
up in this cohort. After all, PCI can only treat angiographically visible disease and not the 
underlying atherosclerotic process that can progress to future lesions. Affordability of health 
care, a major factor determining continued care, has recently been shown to significantly impact 
post-procedural health status following revascularization 71. Even in a field such as PCI, that is 
expanding its patient (and lesion) base, there exist racial differences in choice of devices 
(APPENDIX C). With rising healthcare costs and financial barriers impacting healthcare 
outcomes 94, prescription /recommendation of primary and adjunct therapy do not ensure 
effective and continued management. Now, more than ever, there is pressing need to ensure 
appropriate use of available resources by evaluating cost-effectiveness of treatment. 
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 APPENDIX A: TRENDS IN CARDIOVASCULAR OPERATIONS AND PROCEDURES IN 
THE UNITED STATES (1979-2003) 
      
Figure A.1: Trends in cardiovascular operations and procedures in the United States 
(1979-2003) 
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 APPENDIX B: PARTICIPATING CLINICAL CENTERS IN THE NHLBI-SPONSORED 
1985-86 PTCA AND DYNAMIC REGISTRIES
Table A.1: Clinical centers participating in the NH-BI sponsored 1985-86 PTCA and 
1997-2004 Dynamic Registries 
Boston Medical Center 
Cardiovascular Med. Associates, Houston 
Emory University 
IKEM 
Lankenau Hospital 
Mayo Clinic 
Medical College of Virginia 
Montefiore Medical Center 
Montreal Heart Institute 
New York University – Bellevue 
New York University - Tisch 
Piedmont Hospital 
Presbyterian Medical Center 
Providence/St. Vincent - Portland 
Rhode Island Hospital 
Seton Medical Center 
St. Lukes Medical Center 
St. Lukes/Roosevelt Hospital - NY 
University of Southern California 
University of Chicago 
University of Maryland Hospital 
University of Pennsylvania 
UPMC Presbyterian University Hospital 
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 APPENDIX C: USE OF STENTS AMONG HOSPITALIZED PATIENTS UNDERGOING 
CORONARY ANGIOPLASTY, BY RACE, IN THE UNITED STATES (2003) 
 
Source: Morbidity and mortality weekly report 95  
Figure A.2: Use of stents among hospitalized patients undergoing Coronary 
angioplasty, by Race in the United States (2003) 
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